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Abstract  28 
The tyrosine kinase inhibitor Sunitinib is used to treat cancer and is linked to severe adverse 29 
cardiovascular events. Mitogen activated kinase kinase 7 (MKK7) is involved in the 30 
development of cardiac injury and is a component of the c-Jun N-terminal kinase (JNK) 31 
signal transduction pathway. Apoptosis signal-regulating kinase 1 (ASK1) is the upstream 32 
activator of MKK7 and is specifically inhibited by 2,7-dihydro-2,7-dioxo-3H-naphtho[1,2,3-33 
de]quinoline-1-carboxylic acid ethyl ester (NQDI-1). This study investigates the role of ASK1, 34 
MKK7 and JNK during Sunitinib-induced cardiotoxicity. 35 
 36 
Infarct size were measured in isolated male Sprague-Dawley rat Langendorff perfused 37 
hearts treated for 125 min with Sunitinib in the presence and absence of NQDI-1. Left 38 
ventricular cardiac tissue samples were analysed by qRT-PCR for MKK7 mRNA expression 39 
and cardiotoxicity associated microRNAs (miR-1, miR-27a, miR-133a and miR-133b) or 40 
Western blot analysis to measure ASK1/MKK7/JNK phosphorylation.  41 
  42 
Administration of Sunitinib (1 µM) during Langendorff perfusion resulted in increased infarct 43 
size, increased miR-133a expression, and decreased phosphorylation of the 44 
ASK1/MKK7/JNK pathway compared to control. Co-administration of NQDI-1 (2.5 µM) 45 
attenuated the increased Sunitinib-induced infarct size, reversed miR-133a expression and 46 
restored phosphorylated levels of ASK1/MKK7/JNK. These findings suggest that the 47 
ASK1/MKK7/JNK intracellular signalling pathway is important in Sunitinib-induced 48 
cardiotoxicity. The anti-cancer properties of Sunitinib were also assessed using the 3-(4,5-49 
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell viability assay.  Sunitinib 50 
significantly decreased the cell viability of human acute myeloid leukemia 60 cell line (HL60). 51 
The combination of Sunitinib (1 nM - 10 µM) with NQDI-1 (2.5 µM) enhanced the cancer-52 
fighting properties of Sunitinib. Investigations into the ASK1/MKK7/JNK transduction 53 
pathway could lead to development of cardioprotective adjunct therapy, which could prevent 54 
Sunitinib-induced cardiac injury. 55 
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 65 
1. Introduction  66 
The tyrosine kinase inhibitor Sunitinib is used in the treatment of renal cell carcinoma and in 67 
gastrointestinal stromal tumours (Faivre et al. 2007). Sunitinib prevents tumour cell survival 68 
and angiogenesis by inhibiting a variety of growth factor and cytokine receptors, including 69 
platelet derived growth factor receptors, vascular endothelial growth factor receptors and 70 
proto-oncogenes c-Kit and RET. However, Sunitinib unfortunately is also associated with a 71 
lack of kinase selectivity resulting in the cardiotoxic adverse effects (Force et al. 2007). In 72 
the clinic, Sunitinib causes QT prolongation (Bello et al. 2009),left ventricular dysfunction 73 
(Shah and Morganroth 2015) and heart failure (Ewer et al. 2014).  These findings are 74 
consistent with many other successful chemotherapy agents linked with severe drug-induced 75 
cardiotoxicity (Hahn et al. 2014), including electrophysiological changes and left ventricular 76 
dysfunction which can cause heart failure in some patients (Aggarwal et al. 2013). 77 
Intracellular studies using animals have revealed that Sunitinib causes mitochondrial injury 78 
and cardiomyocyte apoptosis through an increase in caspase-9 and cytochrome C release in 79 
both mice and in cultured rat cardiomyocytes (Chu et al. 2007). Other indicators of 80 
apoptosis, such as an increase in caspase-3/7, have also been detected after Sunitinib 81 
treatment in rat myocytes (Hasinoff et al. 2008). 82 
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 83 
MKK7 is a member of the mitogen-activated protein kinase kinase super family, which allows 84 
the cell to respond to exogenous and endogenous stimuli (Foltz et al. 1998), and furthermore 85 
MKK7 has shown to demonstrate a key role in protecting the heart from hypertrophic 86 
remodelling, which occurs via cardiomyocyte apoptosis and heart failure (Liu et al. 2011). 87 
The MKK7 activation of JNK results in many cellular processes including: proliferation, 88 
differentiation and apoptosis (Chang and Karin 2001; Schramek et al. 2011; Sundarrajan et 89 
al. 2003), and JNK signalling is vital for the maintenance and organisation of the 90 
cytoskeleton and sarcomere structure in cardiomyocytes (Windak et al. 2013). Interestingly, 91 
Sunitinib is an ATP analogue and competitively inhibits the ATP binding domain of its target 92 
proteins (Roskoski 2007; Shukla et al. 2009). MKK7 also contains a highly conserved ATP 93 
binding domain (Song et al. 2013). It is possible that Sunitinib binds as a ligand in the MKK7 94 
ATP binding pocket, and thereby Sunitinib inhibits the MKK7/JNK transduction pathway, and 95 
as a result this could potentially cause myocardial injury. It is important to determine the 96 
relationship between MKK7 expression and Sunitinib induced cardiotoxicity by measuring 97 
the alteration of MKK7 mRNA and phosphorylated MKK7 levels in the presence of Sunitinib. 98 
Unravelling the relationship between Sunitinib and MKK7 could lead to a greater 99 
understanding of its off-target mechanism of action and lead to the improvement in the 100 
development of future drug discovery programmes or novel cardioprotective adjunct 101 
therapies. 102 
 103 
Short non-coding RNA microRNAs carry out the negative regulation of mRNA transcripts by 104 
repressing translation (Bagga et al. 2005). Specific microRNAs expression patterns have 105 
been linked to cardiomyocyte differentiation and in response to stress (Babiarz et al. 2012) 106 
and have also been shown to be differentially expressed during the development of heart 107 
failure (Thum et al. 2007). The microRNAs miR-1, miR-27a, miR-133a and miR-133b 108 
produce differential expression patterns during the progression of heart failure (Akat et al. 109 
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2014; Tijsen et al. 2012). It is important to identify microRNA expression profiles in response 110 
to drug-induced cardiotoxicity as similar patterns in microRNA expression to those identified 111 
during heart failure may indicate the early onset of cardiotoxicity at a molecular level.  112 
 113 
As MKK7 has no direct inhibitor, we have chosen to look at the upstream kinase ASK1 114 
linked to MKK7 activation (Ichijo et al. 1997). ASK1 is activated in response to oxidative 115 
stress-induced cardiac vascular endothelial growth factor suppression in the heart (Nako et 116 
al. 2012). Izumiya et al. 2003 used ASK1 deficient transgenic mice to assess the role of 117 
ASK1 in angiotensin II induced hypertension and cardiac hypertrophy. Both the wild type and 118 
ASK1 deficient mice developed hypertension when stimulated with angiotensin II, however, 119 
the ASK1 deficient mice lacked cardiac hypertrophy and remodelling and activation of ASK1, 120 
p38 and JNK was severely attenuated, thus emphasising the importance of ASK1 in cardiac 121 
hypertrophy and remodelling signalling (Izumiya et al. 2003). ASK1 is selectively inhibited by 122 
NQDI-1 with high specificity with a Ki of 500nM and IC50 of 3µM (Volynets et al. 2011), 123 
however, as this is a relatively new drug, a complete pharmacological profile has not yet 124 
been fully characterised. ASK1 inhibition has previously been shown to offer protection 125 
against ischemia reperfusion injury (Toldo et al. 2012) and has also been shown to suppress 126 
the progression of ventricular remodelling and fibrosis in hamsters expressing severe 127 
cardiomyopathy phenotypes (Hikoso et al. 2007). These findings highlight the potential of 128 
NQDI-1 as a valuable asset to inhibit cardiac injury via the ASK1/MKK7/JNK pathway. 129 
 130 
This novel study investigated the involvement of the ASK1/MKK7/JNK pathway in the 131 
Sunitinib-induced cardiotoxicity via the assessment of cardiac function and infarct in 132 
conjunction with relevant intracellular signalling mediators. Furthermore, we assessed the 133 
anti-cancer properties of Sunitinib and determined whether co-administration of Sunitinib 134 
with NQDI-1 affected the anti-cancer/apoptotic effect of Sunitinib in HL60 cells.  135 
 136 
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2. Materials and Methods  137 
2.1. Main reagents and kits 138 
Sunitinib malate and NQDI-1 were purchased from Sigma Aldrich (UK). Both drugs were 139 
dissolved in dimethyl sulphoxide (DMSO) and stored at -20 °C. Krebs perfusate salts were 140 
from either VWR International (UK) or Fisher Scientific (UK). Total ASK1 (Catalogue no 141 
ab131506) was purchased from Abcam (UK). Phospho-ASK1 (Thr 845) (Catalogue no 142 
3765S), Phospho-MKK7 (Ser271/Thr275) (Catalogue no 4171S), Total MKK7 (Catalogue no 143 
4172S), Phospho-SAPK/JNK (Thr183/Tyr185) (Catalogue no 9251), Total SAPK/JNK rabbit 144 
mAb antibody (Catalogue no 9252), anti-rabbit IgG, HRP-linked antibody and anti-biotin, 145 
HRP-linked antibody were purchased from Cell signalling technologies (UK). All the 146 
primary antibodies were from a rabbit host, and MKK7 and JNK were monoclonal antibodies, 147 
whereas ASK1 was polyclonal (all antibodies were validated by the manufacturers). The 148 
Ambion MicroPoly(A)Puris kit, Ambion mirVana miRNA Isolation Kit and Reverse 149 
Transcription Kit were from Life Technologies (USA). The mRNA primers and the Applied 150 
Biosystems primers assays (U6, rno-miR-1, hsa-miR-27a, hsa-miR-133a, and hsa-miR-151 
133b) were purchased from Invitrogen (UK). The iTaq Universal SYBR Green Supermix was 152 
purchased from BioRad (UK). The HL60 cell line were obtained from European Collection of 153 
Cell Culture (UK) (catalogue no. 98070106). 154 
 155 
2.2. Animals  156 
Adult male Sprague-Dawley rats (300-350 g in body weight); were purchased from Charles 157 
River UK Ltd (UK) and housed suitably. They received humane care and had free access to 158 
standard diet according to the Guide for the Care and Use of Laboratory Animals published 159 
by the US National Institute of Health (NIH Publication No. 85-23, revised 1996). Animals 160 
were selected at random for all treatment groups and the collected tissue was blinded for 161 
infarct size assessment. The experiments were performed following approval of the protocol 162 
by the Coventry University Ethics Committee. All efforts were made to minimise animal 163 
suffering and to reduce the number of animals used in the experiments. Rats were sacrificed 164 
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by cervical dislocation (Schedule 1 Home Office procedure). A total of 80 animals were used 165 
for this study and the data from 68 rats were included, while data from 12 rats were excluded 166 
from analysis due to the established haemodynamic exclusion criteria. A total of 16 animals 167 
were included for Langendorff perfusion experiments per main groups (Control, Sunitinib, 168 
Sunitinib+NQDI-1, and NQDI-1, where 6 of the animals were used for measurement of the 169 
area of infarct and the area of risk and the left ventricular tissue from another 10 animals 170 
was used for real time PCR and Western blot analysis). Furthermore, an additional 4 171 
animals were used for Langendorff perfusion experiments with Sorbitol as a positive control 172 
for p-MKK7 Western blot analysis. No animals were culled due to ill health.   173 
 174 
2.3. Langendorff perfusion model  175 
The hearts were rapidly excised after the rats were culled and placed into ice-cold Krebs 176 
Henseleit buffer (118.5 mM NaCl, 25 mM NaHCO3, 4.8 mM KCl, 1.2 mM MgSO4, 1.2 mM 177 
KH2PO4, 1.7 mM CaCl2, and 12 mM glucose, pH7.4). The hearts were mounted onto the 178 
Langendorff system and retrogradely perfused with Krebs Henseleit buffer. The pH of the 179 
Krebs Henseleit buffer was maintained at 7.4 by gassing continuously with 95 % O2 and 5 % 180 
CO2 and maintained at 37 ± 0.5 °C using a water-jacketed organ chamber. Each 181 
Langendorff experiment was carried out for 145 minutes: a 20 minute stabilisation period 182 
and 125 minutes of drug or vehicle perfusion in normoxic conditions. Hearts were included in 183 
the study with a CF between 3.5-12.0 ml/g (weight of the rat heart) during the stabilisation 184 
period. Sunitinib malate (1 µM) was administered throughout the perfusion period in the 185 
presence or absence of NQDI-1 (2.5 µM).  186 
   187 
The clinically relevant dose of 1 µM Sunitinib was chosen in line with previous studies by 188 
(Henderson et al. 2013). Additionally, it has been reported that the plasma concentration of 189 
Sunitinib has a Cmax in the rage of 0.5–1.4µM (Doherty et al. 2013).  While, the dose of 2.5 190 
µM NQDI-1 was chosen following a thorough literature review (Eaton et al. 2014; Song et al. 191 
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2015; Volynets et al. 2011). NQDI-1 is not yet used in the clinic, therefore a clinically relevant 192 
dose has not been reported. 193 
 194 
Langendorff perfused hearts treated with vehicle were analysed as the control group. The 195 
hearts were then weighed and either stored at -20 °C for 2,3,5-triphenyl-2H-tetrazolium 196 
chloride (TTC) staining or the left ventricular tissue was dissected free and immersed in 197 
RNAlater from Ambion (USA) for qRT-PCR or snap frozen by liquid nitrogen for Western blot 198 
analysis. 199 
 200 
2.4. Infarct size analysis  201 
Frozen whole hearts were sliced into approximately 2 mm thick transverse sections and 202 
incubated in 0.1 % TTC solution in phosphate buffer (2 ml of 100 mM NaH2PO4.2H2O and 8 203 
ml of 100 mM NaH2PO4) at 37 °C for 15 minutes and fixed in 10% formaldehyde (Fisher 204 
Scientific, UK) for 4 hours. The risk zone and infarct areas were traced onto acetate sheets.  205 
The tissue at risk stained red and infarct tissue appeared pale. The acetate sheet was 206 
scanned and ImageTool from UTHSCSA (USA) software was used to measure the area of 207 
infarct and the area of risk. A ratio of infarct to risk size was calculated as a percentage for 208 
each slice. An average was taken of all of the slices from each heart to give the percentage 209 
infarct size of the whole heart. The mean of infarct to risk ratio for each treatment group and 210 
the mean ± SEM was plotted as a bar chart. The infarct size determination was randomised 211 
and blinded. 212 
 213 
2.5. Analysis of microRNA expression profiles 214 
The microRNA was isolated from left ventricular tissue using the mirVana™ miRNA Isolation 215 
Kit from Ambion (UK). The microRNA quantity and quality was measured by NanoDrop from 216 
Nanoid Technology (USA).  A total of 500 ng microRNA was reverse transcribed into cDNA 217 
using primers specific for housekeeping reference RNA U6 snRNA and target microRNAs: 218 
hsa-miR-155, hsa-miR-15a, hsa-miR-16-1, rno-miR-1, hsa-miR-27a, hsa-miR-133a or hsa-219 
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miR-133b (please note all human hsa-miR assays are compatible with rat samples) from 220 
Applied Biosystems (USA) using the MicroRNA Reverse Transcription Kit from Applied 221 
Biosystems (USA) according to the manufacturer's instructions. The reverse transcription 222 
quantitative PCR reaction was performed with the following setup: 16 °C for 30 min, 42°C for 223 
30 min and 85 °C for 5 min and ∞ at 4°C. The qRT-PCR was performed using the TaqMan 224 
Universal PCR Master Mix II (no UNG) from Applied Biosystems (USA) protocol on the 7500 225 
HT Real Time PCR sequence detection system from Applied Biosystems (USA). A 20μl 226 
reaction mixture containing 100 ng cDNA, specific primer assays mentioned above from 227 
Applied Biosystems (USA) and the TaqMan Universal PCR Master Mix was used in the qRT-228 
PCR reaction in triplicates.  A non-template control was included in all experiments. The real 229 
time PCR reaction was performed using the program: 1) 2 minutes at 50°C, 2) 10 minutes at 230 
95°C, 3) 15 seconds at 95°C, 4) 1 minute at 60°C. Steps 3) and 4) were repeated 40 times. 231 
 232 
Analysis of qRT-PCR data of microRNAs were performed using the Ct values for U6 snRNA 233 
as reference for the comparison of the relative amount of microRNAs (rno-miR-1, hsa-miR-234 
27a, hsa-miR-133a and hsa-miR-133b). The values of each of the microRNAs were 235 
calculated to compare their ratios. The formula used was X0/R0=2
CTR-CTX, where X0 is the 236 
original amount of target microRNA, R0 is the original amount of U6 snRNA, CTR is the CT 237 
value for U6 snRNA, and CTX is the CT value for the target microRNAs (rno-miR-1, hsa-238 
miR-27a, hsa-miR-133a and hsa-miR-133b) (Sandhu et al. 2010). Averages of the Ct values 239 
for each sample group (Control and Sunitinib treated hearts) and each individual primer set 240 
were calculated, and bar charts were plotted with mean ± SEM.  The mean of the control 241 
group was set as 1 for all microRNAs.  242 
 243 
2.6. Measurement of MKK7 mRNA expression 244 
Total mRNA was extracted from left ventricular tissue using The Ambion MicroPoly(A)Purist 245 
kit from Ambion (USA). Extracted mRNA was processed directly to cDNA by reverse 246 
transcription using Reverse Transcription Kit from Applied Biosystems (USA) with the 247 
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respective primers for MKK7 (MKK7 forward primer: CCCCGTAAAATCACAAAGAAAATCC 248 
and MKK7 reverse primer: GGCGGACACACACTCATAAAACAGA) and GAPDH (GAPDH 249 
Forward primer: GAACGGGAAGCTCACTGG and GAPDH Reverse primer: 250 
GCCTGCTTCACCACCTTCT) according to the instructions from the manufacturer Invitrogen 251 
(UK). The reverse transcription PCR reaction was performed with the following setup: 16 °C 252 
for 30 minutes, 42°C for 30 minutes and 85 °C for 5 minutes. The qRT-PCR reactions were 253 
performed with the iTaq Universal SYBR Green Supermix from BioRad (UK), GAPDH and 254 
MKK7 mRNA primer sets on the 7500 HT Real Time PCR machine from Applied Biosystems 255 
(USA) using the program: 1) 2 minutes at 50°C, 2) 10 minutes at 95°C, 3) 15 seconds at 256 
95°C, 4) 1 minute at 60°C. Steps 3) and 4) were repeated 40 times. 257 
 258 
Analysis of qRT-PCR data of MKK7 mRNA were performed using the Ct values for GAPDH 259 
mRNA as reference for the comparison of the relative amount of MKK7 mRNA. The value of 260 
mRNA was calculated to compare the ratios using the formula X0/R0=2
CTR-CTX, where X0 is 261 
the original amount of target mRNA, R0 is the original amount of GAPDH mRNA, CTR is the 262 
CT value for GAPDH mRNA, and CTX is the CT value for the MKK7 mRNA (Sandhu et al. 263 
2010). Averages of the Ct values for each sample group (control and Sunitinib treated 264 
hearts) and each individual primer set were calculated, and bar charts were plotted with 265 
mean ± SEM.  The mean of the control group was set as 1 for the MKK7 mRNA.  266 
 267 
2.7. Western blot detection of ASK1, MKK7 and JNK 268 
A total 45-55 mg of the frozen left ventricular tissue was lysed in lysis buffer (NaCl 0.1 M, 269 
Tris base 10 µM, EDTA 1 mM, sodium pyrophosphate 2 mM, NaF 2 mM, β-glycaophosphate 270 
2 mM, 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride (0.1 mg/ml, 1/1.5 of protease 271 
cocktail tablet) using a IKA Overtechnical T25homogeniser at 11,000 RPM. The 272 
supernatants were measured for protein content using NanoDrop from Nanoid Technology 273 
(USA). Then 80 µg of protein was loaded to 4–15 % Mini-Protean TGX Gel from BioRad 274 
(UK) and separated at 200 V for 60 minutes. After separation, the proteins were transferred 275 
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to the Bond-P polyvinylidene difluoride membrane from BioRad (UK) by using the Trans-Blot 276 
Turbo transfer system from BioRad (UK) and probed for the phosphorylated forms 277 
Phospho(Thr845)-ASK1 (p-ASK1), Phospho(Ser271/Thr275)-MKK7 (p-MKK7) and 278 
Phospho(Thr183/Tyr185) -SAPK/JNK (p-JNK), and total forms of ASK1(Thr845), 279 
MKK7(Ser271/Thr275) and JNK(Thr183/Tyr185). The p-MKK7 and p-JNK blots were stripped by 280 
boiling and the PVDF membrane was used for total MKK7 and total JNK analysis, 281 
respectively. According to recommendations from Cell signalling technologies (UK) total 282 
ASK1 analysis had to be performed on a separate Western blot, as the stripping procedure 283 
would remove total ASK1 protein. The relative changes in the p-ASK1, p-MKK7 and p-JNK 284 
protein levels were measured and corrected for differences in protein loading as established 285 
by probing for total ASK1, MKK7 and JNK respectively. 286 
 287 
For Western blot analysis phosphorylated antibody levels were normalised to total antibody 288 
levels in order to correlate for unequal loading of protein and differential blot transfer and to 289 
identify the level of active vs inactive protein levels. Results were expressed as a percentage 290 
of the density of phosphorylated protein relative to the density of total protein using Image 291 
Lab 4.1 from BioRad (UK). The phosphorylated antibody levels determination was 292 
randomised and blinded.  293 
 294 
2.8. MTT assay assessment of HL60 cell viability in the presence of Sunitinib with and 295 
without NQDI-1 296 
The HL60 cell line were maintained in in RPMI 1640 medium supplemented with L-297 
Glutamine (2 mM) and 10 % heat-inactivated fetal bovine serum and antibiotics mix at 37 °C 298 
in a humidiﬁed incubator under 5 % CO2/95 % air. Cells were split in a 1:5 ratio every 2-3 299 
days. Cells were incubated with Control, increasing concentrations of Sunitinib (1nM – 10 300 
μM), Sunitinib (0.1 – 10 μM) + NQDI-1 (2.5 µM), or increasing concentrations of NQDI-1 301 
(0.2-200 µM) for 24 h. Both Sunitinib and NQDI-1 were dissolved in DMSO. The DMSO 302 
concentration was < 0.05 % (v/v) during the in vitro studies.  303 
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 304 
Cells were plated at a cell density of 105 cells/ml in 96-well plates and the above indicated 305 
concentration of the drug was added. The plate was then incubated at 37°C for 24hrs. After 306 
drug incubation, 50 µl of MTT solution (5 mg MTT/ml H2O) was added and the cells were 307 
incubated for a further 24 h. Next, 50 µl of DMSO was added to each well and mixed by 308 
pipetting to release reduced MTT crystals from the cells. Relative cell viability was obtained 309 
by scanning with an ELISA reader (Anthos Labtech AR 2001 Multiplate Reader, Anthos 310 
Labtec Instruments, Austria) with a 490 nm ﬁlter. Results were expressed as a percentage of 311 
viable cells relative to untreated cells/control. Experiments were performed in triplicates and 312 
repeated ≥ 3 times. 313 
 314 
2.9. Statistical analysis 315 
Results are presented as mean ± standard error of the mean (SEM). Significance of all data 316 
sets was measured by one-way ANOVA analysis with the Tukey post hoc test using the 317 
Matlab prism program. The following groups were compared during ANOVA analysis: 318 
Control versus Sunitinib, Control versus Sunitinib and NQDI-1, Control versus NQDI-1 (all 319 
statistically significant data compared to control marked with *), and Sunitinib versus 320 
Sunitinib and NQDI-1 (all statistically significant data compared to Sunitinib marked with #). 321 
For MKK7 mRNA some data was evaluated by using student’s t-test. P-values <0.05 were 322 
considered statistically significant. 323 
 324 
3. Results 325 
3.1. Sunitinib treatment induces cardiac injury  326 
The effect of Sunitinib (1µM) administration on myocardial infarction development was 327 
investigated by TTC staining. The hearts were stabilised for a period of 20 minutes, followed 328 
by 125 minutes of drug perfusion. Administration of Sunitinib (1µM) for 125 minutes resulted 329 
in a significant increase in infarct size compared with non-treated controls (Control: 7.81 ± 330 
1.16 %; Sunitinib: 41.02 ± 1.23 %, p<0.001) (Fig 1). This demonstrated that Sunitinib 331 
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treatment of the Langendorff perfused hearts results in a drastic increase in cardiac injury. 332 
The infarct was globally distributed in all groups investigated in this study (i.e. Control, 333 
Sunitinib ± NQDI-1, and NQDI-1). 334 
 335 
3.2. Sunitinib and NQDI-1 co-treatment alleviate cardiac injury  336 
The effect of ASK1 inhibition by NQDI-1 on cardiac function and infarction was investigated.  337 
Co-administration of Sunitinib (1 µM) with NQDI-1 (2.5 µM) significantly decreased infarct 338 
size compared to Sunitinib treated hearts (Sunitinib: 41.02 ± 1.23 %; Sunitinib + NQDI-1: 339 
17.54 ± 2.97 %, p<0.001). However, administration of NQDI-1 alone for 125 minutes of 340 
perfusion significantly increased infarct size compared with control hearts (Control: 7.81 ± 341 
1.16 %; NQDI-1: 16.68 ± 2.66 %, p<0.05) (Fig 1). 342 
 343 
3.3. Sunitinib treatment modulates expression of microRNAs involved in cardiac 344 
injury 345 
The expression of cardiac injury specific microRNAs during Sunitinib-induced cardiotoxicity 346 
was determined by qRT-PCR assessment. The microRNAs miR-1, miR-27a, miR-133a and 347 
miR-133b have been shown to produce differential expression patterns during the 348 
progression of heart failure. The ratio of target microRNA normalised to U6 was set to 1 in 349 
the control group for easier comparison of microRNA ratio values between the various drug 350 
therapy groups.  There was a significant increase in miR-133a when hearts were perfused 351 
with Sunitinib (1 µM) compared to control hearts (Ratio of target microRNA normalised to U6 352 
in Sunitinib treated hearts: miR-133a: 535.78 ± 61.27, p<0.001). Co-administration of NQDI-353 
1 (2.5 µM) along with Sunitinib reversed this miR-133a expression trend by decreasing the 354 
miR-133a expression when compared to Sunitinib perfused hearts (Ratio of target microRNA 355 
normalised to U6 in Sunitinib and NQDI-1 treated hearts: miR-133a: 52.76 ± 28.30, 356 
p<0.001). Hearts perfused with NQDI-1 alone showed an increase in miR-1, miR-27a and 357 
miR-133b expression compared to control hearts (Ratio of target microRNA normalised to 358 
U6 in NQDI-1 treated hearts: miR-1: 32.33 ± 16.47, p<0.01; miR-27a: 11.27 ± 2.86, p<0.001; 359 
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miR-133b: 167.85 ± 58.13, p<0.001). The expression of miR-1, miR-27a, miR-133a and 360 
miR-133b was increased in the Sunitinib and NQDI-1 co-treated hearts when compared to 361 
Sunitinib perfused hearts (miR-1: p<0.05; miR-27a: p<0.001; miR-133a: p<0.001; miR-133b: 362 
p<0.05). (Fig 2 A-D). 363 
 364 
The results from the microRNA qRT-PCR analysis show there is a similar expression pattern 365 
for miR-1, miR-27 and miR-133b, while miR-133a has its own pattern. This indicates that the 366 
cardiac injury induced by Sunitinib, which is alleviated by the ASK1 inhibitor NQDI-1, triggers 367 
a complex alteration of these cardiac injury microRNAs. Further studies looking at the 368 
altered expression profiles for these cardiac injury microRNAs have to be undertaken in 369 
order to clarify the expression patterns. 370 
 371 
3.4. MKK7 mRNA expression profile is altered by ASK1 inhibitor NQDI-1 372 
As MKK7 contains an ATP binding domain (Song et al. 2013) and Sunitinib is an ATP 373 
analogue and competitively inhibits the ATP binding domain of its target proteins (Roskoski 374 
2007; Shukla et al. 2009). We therefore wanted to investigate the interaction between 375 
Sunitinib and MKK7, and question whether Sunitinib could bind as a ligand in the ATP 376 
binding pocket of MKK7. This would determine if Sunitinib might potentially have an 377 
inhibitory effect on the MKK7/JNK pathway. The relationship between MKK7 expression and 378 
Sunitinib-induced cardiotoxicity was assessing on transcriptional level by MKK7 mRNA qRT-379 
PCR analysis on Sunitinib (1 µM) perfused hearts, and the interaction by ASK1 specific 380 
inhibitor NQDI-1 was detected to highlight if any interaction between ASK1/MKK7 and 381 
Sunitinib-induced alteration of MKK7 transcription due to cardiac injury was observed to 382 
impact on mRNA levels.  The ratio of MKK7 mRNA normalised to GAPDH was set to 1 in the 383 
control group for easier comparison of GAPDH normalised MKK7 mRNA values between the 384 
various drug therapy groups. The qRT-PCR analysis of MKK7 mRNA revealed that co-385 
administration of NQDI-1with Sunitinib caused a significant increase in MKK7 mRNA 386 
expression compared to Sunitinib treatment alone (p<0.01) (Ratio of MKK7 mRNA 387 
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normalised to GAPDH. Sunitinib: 0.12 ± 0.03; Sunitinib + NQDI-1: 1.18 ± 0.65) (Fig 3). The 388 
decrease in MKK7 mRNA observed in the Sunitinib (1 µM) perfused hearts compared to 389 
control hearts was not significant, but a clear trend was observed. If the data from groups 390 
control and Sunitinib were compared using a Student’s t-test the decline in MKK7 mRNA in 391 
Sunitinib treated hearts was statistically significant with p=0.0043. 392 
 393 
These MKK7 mRNA qRT-PCR results clearly demonstrate that Sunitinib treatment shows a 394 
tendency to decrease the MKK7 mRNA, and co-administration of ASK1 specific inhibitor 395 
NQDI-1 restores the MKK7 mRNA level observed in control treated heart. This could indicate 396 
a complex regulation system where Sunitinib-induced cardiac injury in directly linked with the 397 
ability of Sunitinib to reduced MKK7 expression at transcriptional level, which is counteracted 398 
by the ASK1 specific inhibitor NQDI-1. 399 
 400 
3.5. ASK1/MKK7/JNK pathway is involved in Sunitinib-induced cardiotoxicity 401 
As explained in the previous MKK7 mRNA results section we wanted to investigate the 402 
interaction between Sunitinib and MKK7, as they both interact via the ATP binding pocket. 403 
The key question being if Sunitinib can bind as a ligand in the ATP binding pocket of MKK7 404 
and if Sunitinib is able to block the MKK7/JNK pathway. Here we investigate the role of 405 
cardiotoxic Sunitinib therapy on the ASK1/MKK7/JNK pathway phosphorylation and how the 406 
interaction with the cardioprotective ASK1 specific agent NQDI-1 effects the 407 
ASK1/MKK7/JNK pathway phosphorylation. Following Langendorff perfusion of Sunitinib and 408 
NQDI-1, p-ASK1, p-MKK7 and p-JNK levels were measured in the left ventricular tissue of 409 
the hearts by Western blot analysis.  410 
 411 
Western blot analysis showed that Sunitinib treatment decreased p-ASK1, p-MKK7 and p-412 
JNK levels significantly when compared to control (density of phosphorylated protein 413 
normalised to total protein:  p-ASK1: Control: 389.43 ± 4.18 and Sunitinib: 16.47 ± 3.56, 414 
p<0.001; p-MKK7: Control: 55.60 ± 4.86 and Sunitinib: 23.66 ± 4.53, p<0.001; p-JNK:  415 
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Control: 43.66 ± 2.82 and Sunitinib: 22.52 ± 2.74, p<0.001). Co-administration with NQDI-1 416 
increased the p-ASK1, p-MKK7 and p-JNK levels, and these were statistically significantly 417 
elevated when compared to heart treated with Sunitinib monotherapy (density of 418 
phosphorylated protein normalised to total protein: p-ASK1: Sunitinib + NQDI-1: 51.17 ± 419 
3.66, p<0.001; p-MKK7: Sunitinib + NQDI-1: 38.11 ± 1.87, p<0.05; p-JNK: 48.95 ± 2.76, 420 
p<0.001). The p-ASK1, p-MKK7 and p-JNK levels were decreased in NQDI-1 treated hearts 421 
compared to control hearts (density of phosphorylated protein normalised to total protein: p-422 
ASK1: NQDI-1: 20.56 ±1.99, p<0.01; p-MKK7: NQDI-1: 18.40 ± 2.98, p<0.001; p-JNK: 28.78 423 
± 3.03, p<0.01) (Fig 4A-C).  424 
  425 
These Western blot results show that Sunitinib decreased the phosphorylation of the 426 
ASK1/MKK7/JNK pathway. The fact that Sunitinib was able to show a strong tendency of 427 
decreasing the MKK7 mRNA highlights that the decreased MKK7 phosphorylation is 428 
regulated at the transcriptional level, which is then affecting the post-transcriptional MKK7 429 
phosphorylation levels. However, interestingly the cardiotoxic Sunitinib is having an inhibiting 430 
effect throughout all three parts of the ASK1/MKK7/JNK pathway. Co-administration of 431 
NQDI-1 is counteracting the Sunitinib inhibiting effect on the phosphorylation level 432 
throughout the ASK1/MKK7/JNK pathway. These results show a clear indication of Sunitinib 433 
interacting with ASK1, MKK7 and JNK at post-translational level and MKK7 gene expression 434 
at pre-transcriptional level.  435 
 436 
3.6. Cancer cell viability in response to Sunitinib with and without NQDI-1 437 
The effect of Sunitinib on cell viability was examined in HL60 cells. The HL60 cells were 438 
treated with Sunitinib for 24 hrs and then the level of mitochondrial metabolic-activity 439 
inhibition was measured with the MTT assay. Sunitinib showed a pronounced decrease in 440 
metabolic activity and a dose-dependent decrease in cell viability (Fig 5A). In particular, 441 
Sunitinib significantly reduces cell viability at 1 nM (82.62 ± 6.55 %, p<0.05), 0.1 µM (85.94 ± 442 
3.80 %, p<0.05), 0.5 µM (83.94 ± 3.86 %, p<0.05), 1 µM (77.28 ± 6.58 %, p<0.05), 5 µM 443 
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(58.61 ± 4.44 % p<0.001) and 10 µM (47.14 ± 6.77 %, p<0.001) concentrations of Sunitinib. 444 
The IC50 value was 6.16 µM. All the concentrations of Sunitinib in the absence and presence 445 
of NQDI-1 used during this study produced significant reductions in HL60 cell viability 446 
compared to vehicle treatment. 447 
 448 
The co-administration of NQDI-1 (2.5 µM) to increasing concentrations of Sunitinib (1 nM - 449 
10 µM) enhanced the inhibition of mitochondrial metabolism shown by Sunitinib (Fig 5A). 450 
Specifically, co-treatment of Sunitinib with NQDI-1 reduced cell viability at 1 µM (59.58 ± 451 
6.30 %, p<0.001), 5 µM (36.62 ± 6.52 %, p<0.001) and 10 µM (15.10 ± 2.31 %, p< 0.001) 452 
concentrations of Sunitinib compared to Sunitinib alone. The IC50 value for Sunitinib plus 453 
NQDI-1 was 1.76 µM. 454 
 455 
Interestingly, increasing concentrations of NQDI-1 alone (0.2-200 µM) only significantly 456 
reduced cell viability at very high concentrations. Reductions in cell viability were significant 457 
at 100 µM (55.44 ± 12.39 %, p<0.05), 200 µM (33.15± 9.67 %, p<0.001) (Fig 5B). The IC50 458 
value for NQDI-1 produced by the MTT assay was 130.8 µM. 459 
 460 
4. Discussion  461 
4.1. Involvement of ASK1/MKK7/JNK in Sunitinib-induced cardiotoxicity  462 
The occurrence heart failure associated with anti-cancer treatment has been investigated 463 
extensively (Khakoo et al. 2008), however, the underlying mechanism of cardiotoxicity is still 464 
unclear. Determining cellular pathways involved in Sunitinib-induced cardiotoxicity could help 465 
to develop therapies which could prevent the potential development of heart failure 466 
associated with Sunitinib treatment. 467 
 468 
Data presented in this study confirms that Sunitinib causes drug-induced myocardial injury 469 
via an increase in infarct size (Fig 1). We observed that infarct size increased from ~ 8 % in 470 
Control hearts to ~ 41 % in hearts perfused with Sunitinib. This observation is in accordance 471 
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with our previous study, where we investigated the involvement of A3 adenosine receptor 472 
activation during Sunitinib induced cardiotoxicity in perfused rat hearts (Sandhu et al. 2017). 473 
Also, the injury induced by Sunitinib administration is very similar to ischemia/reperfusion 474 
injury rats investigated by the same Langendorff model (Gharanei et al. 2013). The Control 475 
rat hearts do suffer from minor infarct injury during the brief period it takes from sacrificing 476 
the animal and perfusing the heart with the Krebs buffer during the Langendorff model. This 477 
insult accounts for the ~ 8 % infarct size we observe in Control hearts. A dose of 1 µM 478 
Sunitinib increased the infarct to ~ 41 % in perfused heart, and this steady state blood 479 
concentration of Sunitinib has been found in patients treated with Sunitinib (Henderson et al. 480 
2013). As the rat hearts are physically much smaller than human hearts, the rat hearts may 481 
have been more sensitive to the adverse effect of Sunitinib administration at the clinically 482 
relevant dose of 1 µM.  483 
 484 
Other animal studies investigating Sunitinib-induced cardiotoxicity were linked to a significant 485 
decrease in left ventricular function (Henderson et al. 2013; Mooney et al. 2015), and 486 
interestingly left ventricular dysfunction has also been identified in patients undergoing 487 
Sunitinib chemotherapy (Di Lorenzo et al. 2009). Also, Sunitinib has also been associated 488 
with electrophysiological disturbances and an increased pro-arrhythmic relative risk of 489 
developing QTc interval prolongation (Ghatalia et al. 2015; Schmidinger et al. 2008).  490 
Several studies show that Sunitinib could potentially block human ether-a-go-go-related 491 
gene (hERG) potassium channels and cause irregular contractions (Doherty et al. 2013; Guo 492 
et al. 2013). The in vitro study by Thijs et al. 2015 investigated the effect of Sunitinib on the 493 
contractile force measured during normal pacing or after simulated ischemia on isolated 494 
human atrial trabeculae from patients awaiting coronary artery bypass graft and/or aorta 495 
valve replacement. They showed that treatment with 81.3 nM Sunitinib did not attenuate the 496 
recovery in contractile force of atrial cardiomyocytes after simulated ischemia and 497 
reperfusion compared to vehicle treated atrial cardiomyocytes, and thus they concluded that 498 
the development of heart failure in patients treated with Sunitinib could not be explained by 499 
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an acute cardiotoxic Sunitinib stimulation of cardiomyocytes. However, it should be noted 500 
that they used a 12-times lower Sunitinib dose compared to what we have used in this study, 501 
and thus they might have not used a dose of Sunitinib in the toxic range (Thijs et al. 2015).  502 
 503 
Modulation of ASK1 and its downstream targets MKK7 and JNK have been shown to play 504 
important roles in regulating cardiomyocyte survival, apoptosis, hypertrophic remodeling and 505 
intracellular signalling associated with heart failure (Mitchell et al. 2006). Therefore, we 506 
hypothesised that successful modulation of the ASK1/MKK7/JNK pathway would produce an 507 
effective cardioprotective treatment against Sunitinib induced cardiotoxicity. 508 
 509 
As we were interested in the ASK1/MKK7/JNK signalling pathway we targeted ASK1 with 510 
NQDI-1. Administration of the ASK1 specific inhibitor NQDI-1 resulted in abrogation of the 511 
some cardiotoxic effects of Sunitinib. This study therefore, demonstrates the potentially 512 
pivotal role that this kinase and the related pathway could play in protecting the heart from 513 
Sunitinib induced cardiotoxicity. These observations are in accordance with other studies 514 
that have also implicated the involvement of ASK1 in cardioprotection in other mammalian 515 
models (Boehm 2015; Hao et al. 2016; He et al. 2003). Furthermore, inhibition of ASK1 with 516 
thioredoxin results in reduction of infarct size compared to ischemic/reperfusion control 517 
hearts (Gerczuk et al. 2012; Huang et al. 2015; Zhang et al. 2007).  518 
 519 
ASK1 signalling pathway is facilitated through two main routes: either (i) MKK4/7 and JNK, 520 
or (ii) MKK3/6 and p38 (Ichijo et al. 1997). As mentioned in the introduction the study by 521 
Izumiya et al. 2003 showed the importance of ASK1 during angiotensin II induced 522 
hypertension and cardiac hypertrophy in mice, as ASK1 knockout mice failed to develop 523 
cardiac hypertrophy and remodelling through both JNK and p38 (Izumiya et al. 2003). In 524 
another study by Yamaguchi et al. 2003 knockout of ASK1 in mice was also linked to 525 
cardioprotection through the JNK pathway, as coronary artery ligation or thoracic transverse 526 
aortic constriction in ASK1 deficient hearts showed no morphological or histological defects. 527 
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Both left ventricular end-diastolic and end-systolic ventricular dimensions were increased 528 
less then wild-type mice, and the decreases in fractional shortening in both experimental 529 
models were less when compared with wild-type mice (Yamaguchi et al. 2003). However, in 530 
a study by Taniike et al. 2008 when ASK1 knockout mice were subjected to mechanical 531 
stress it resulted in exaggerated hearth growth and hypertrophy development through p38 532 
pathway (Taniike et al. 2008). It is worth noting that attenuation of ASK1 by NQDI-1 during 533 
normoxic conditions and Sunitinib treatment could have affected the MKK3/6 and p38 534 
signalling pathway, which would have led to the conflicting results that we observe during 535 
our study: there was a significant reduction in infarct size when Sunitinib was administered in 536 
the presence of the ASK-1 inhibitor NQDI-1, however administration of NQDI-1 alone also 537 
increased the infarct size. The increase in infarct size with NQDI-1 was not as profound as 538 
the increase observed with Sunitinib (Fig 1).  539 
 540 
NQDI-1 is a recently discovered highly specific ASK1 inhibitor. In the presence of 25 µM 541 
NQDI-1 the residual activity of ASK1 is reduced to 12.5 % using the ɣ-32P-ATP in vitro 542 
kinase assay model. By using the same assay model Volynetys and colleagues determined 543 
the residual activity of the tyrosine protein kinase fibroblast growth factor receptor 1 (FGFR1) 544 
which was measured to be 44 % after 25 µM NQDI-1 exposure (Volynets et al. 2011). 545 
FGFR1 as a key component involved in in vivo cardiomyocyte proliferation during early 546 
stage heart development (Mima et al. 1995). Furthermore, FGFR1 is an essential regulator 547 
of coronary vascular development through Hedgehog signalling activation, which in the adult 548 
heart leads to increased coronary vessel density (Lavine et al. 2006). It is therefore possible 549 
that NQDI-1 is blocking FGFR1 directly in the treated hearts of our study and thereby 550 
exerting a slight increase in infarct size compared to the control.  551 
 552 
In addition, NQDI-1’s specificity towards other kinases has yet to be determined. In particular 553 
its homologue apoptosis signal-regulating kinase 2 (ASK2) may potentially be inhibited by 554 
NQDI-1 (Hattori et al. 2009). Both ASK1 and ASK2 is expressed in the heart (Iriyama et al. 555 
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2009). ASK2 is only stable and active when it forms a heteromeric complex with ASK1. 556 
ASK2 mediate its stress response from the stable ASK1-ASK2 heteromeric complex 557 
platform through both JNK and p38 and induce apoptosis. Furthermore, ASK1 and AS2 are 558 
able to activate each other, and thus ASK1 assists ASK2 with ASK2 regulatory mechanisms 559 
in addition to stabilising and activating ASK2 (Takeda et al. 2007). It is therefore very likely 560 
that NQDI-1 will affect the ASK2 mediated signalling. Several studies by the team of Kataoka 561 
have revealed the involvement of ASK2 during hypertension, cardiac hypertrophy and 562 
remodelling development. They have shown that ASK2 deficient mice have a significantly 563 
higher blood pressure and increased left ventricular weight then wild type mice, with an 564 
underlying analysis revealing that perivascular and interstitial myocardial fibrosis was 565 
increased (Kataoka 2008, 2009, 2010, 2011). Therefore, the relatively small adverse effect 566 
of NQDI-1 administration on producing an increased infarct size could also be caused by the 567 
NQDI-1 effect through attenuated ASK2 signalling.    568 
 569 
Further studies are required to unravel the underlying mechanisms associated with the 570 
cardiac tissue injury and haemodynamic responses observed upon NQDI-1 stimuli to assess 571 
if p38, FGFR1, and/or ASK2 are involved. Also, other concentration of NQDI-1 treatment of 572 
hearts should be investigated, as lower concentrations of NQDI-1 most likely would cause 573 
less cardiac adverse effects. 574 
 575 
4.2. Profiling of cardiotoxicity linked microRNAs  576 
MicroRNAs have been shown to have important roles in tissue formation and function in 577 
response to injury and disease. The microRNAs miR-1, miR-27a, miR-133a and miR-133b 578 
have been shown to produce differential expression patterns during the progression of heart 579 
failure (Akat et al. 2014; Tijsen et al. 2012). Here we investigate the altered expression 580 
profiles of microRNAs miR-1, miR-27a, miR-133a and miR-133b after Sunitinib-induced 581 
cardiotoxicity with or without the ASK1 inhibitor NQDI-1 (Fig 2A-D). To the best of our 582 
knowledge there are no other studies showing a significant altered expression of miR-1, 583 
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miR-27a, miR-133a and miR-133b after Sunitinib treatment. A reduction in hERG potassium 584 
channels expression causes the delayed myocyte repolarisation attributed to a long QT 585 
interval and interestingly the 3’ untranslated region of hERG potassium channel transcripts 586 
have a partial complimentary miR-133a target site (Xiao et al. 2007). The current study 587 
shows an increase in miR-133a expression following Sunitinib treatment, which was 588 
attenuated with NQDI-1 co-administration (Fig 2C). This could imply that miR-133a 589 
overexpression inhibits the hERG potassium channel, which would have a negative impact 590 
on the electrophysiological response (Xu et al. 2007). Over expression of miR-133a has also 591 
been shown to have negative effects on cardiomyocyte proliferation and survival (Liu et al. 592 
2008), which corroborates the results from the current study.  593 
 594 
In the heart miR-1 and miR-133 maintain the heart beat rhythm by regulating the cardiac 595 
conduction system (Kim 2013). Furthermore, miR-1 and miR-133 are downregulated during 596 
cardiac hypertrophy in both mouse and human models. In vitro studies have shown that the 597 
overexpression of miR-133 inhibits cardiac hypertrophy, whereas inhibition of miR-133 598 
induces more pronounced hypertrophy (Care et al. 2007). In addition, a decreased in cardiac 599 
expression of miR-133b is sufficient to induce hypertrophic gene expression (Sucharov et al. 600 
2008). In support of these studies our analysis shows that the miR-133b expression is 601 
increased during NQDI-1 mono-therapy and co-administration of Sunitinib and NQDI-1 (Fig 602 
2C), thus protecting the heart against hypotrophy/cardiac damage development, which is the 603 
same pattern as we observe in the infarct to risk analysis. 604 
 605 
The miR-27a expression has been observed to downregulate FOXO-1 protein, a 606 
transcription factor which regulates genes involved in the apoptotic response, cell cycle, and 607 
cellular metabolism (Guttilla and White 2009). Moreover, miR-27a is downregulated in 608 
coronary sinus samples of heart failure patients (Marques et al. 2016). The increase in miR-609 
27a expression in our study during NQDI-1 mono-therapy and co-administration of Sunitinib 610 
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and NQDI-1 (Fig 2B) support the findings from these studies as the link increased miR-27 611 
expression to reduced apoptosis, which is what we observe in the infarct to risk analysis.  612 
 613 
4.3. Sunitinib treatment supresses the ASK1/MKK7/JNK pathway 614 
4.3.1. ASK1 615 
Western blot assessment of Sunitinib treated hearts showed a significant decrease in p-616 
ASK1 when compared to control perfused hearts, and this decrease in p-ASK1 levels was 617 
abrogated with NQDI-1 co-administration. However, in p-ASK1 levels from hearts subjected 618 
to Sunitinib and NQDI-1 co-administration were compared to control hearts we did observe a 619 
significant increase in p-ASK1. Furthermore, NQDI-1 treated hearts had significantly 620 
decreased p-ASK1 levels when compared to control hearts (Fig 4A).  621 
 622 
ASK1 has multiple phosphorylation sites. The Akt/protein kinas B complex binds to and 623 
phosphorylates Ser83 of ASK1, resulting in the inhibition of ASK1-mediated apoptosis (Kim et 624 
al. 2001), the 14-3-3 interacts with phosphorylated Ser967 of ASK1 to block the function of 625 
ASK1 (Zhang et al. 1999), protein phosphatase 5 dephosphorylates Thr845 within the 626 
activation loop of ASK1 and thereby inhibits ASK1-mediated apoptosis (Morita et al. 2001), 627 
while Ser1034 phosphorylation suppresses ASK1 proapoptotic function (Fujii et al. 2004). 628 
ASK1 undergoes auto-phosphorylation at the Thr845 (Tobiume et al. 2002). It is possible that 629 
auto-phosphorylation increased when Sunitinib was combined with NQDI-1, which led to the 630 
increased levels of p-ASK1 identified by western blot analysis. In its inactive form, ASK1 is 631 
complexed with thioredoxin (Saitoh et al. 1998). It has been proposed that auto-632 
phosphorylation at Thr845 is increased in response to H2O2 treatment, due to H2O2 preventing 633 
thioredoxin from complexing with ASK1. This suggests that ASK1 activation is due to 634 
oxidative stress (Tobiume et al. 2002).  An increase in p-ASK1 could indicate increased 635 
levels of oxidative stress, which potentially reduced cardiac function and generated a level of 636 
infarct when NQDI-1 was administered alone compared to control.  637 
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 638 
 Attenuation of ASK1 by the specific inhibitor NQDI-1 produces a protective role in the heart 639 
compared to Sunitinib treatment alone. In this study we have focused on the ASK1 Thr845 640 
phosphorylation site, however, in future studies it would be interesting to investigate the 641 
ASK1 Ser967 phosphorylation, as phosphorylation at this site has been linked to 642 
cytoprotection (Kim et al. 2009). Another interesting aspect would be to identify if NQDI-1 is 643 
able to inhibit the ASK1 homologue ASK2 as indicated by Nomura et al. 2013 (Nomura et al. 644 
2013) and establish the Ki and IC50 values are.  645 
 646 
ASK1 is also a key mediator of apoptotic signalling (Hattori et al. 2009; Ichijo et al. 1997) and 647 
the team of Huynh et al. 2011 investigated the expression of ASK1 in tumours lysates from 648 
mice bearing 06-0606 tumours treated with 40 mg/kg/day Sunitinib for 11 days (Huynh et al. 649 
2011). Their study showed a significant increase in total ASK1 levels after Sunitinib 650 
treatment compared to vehicle treated 06-0606 tumour expressing mice, however, in our 651 
study the expression of total ASK1 levels in left ventricular coronary tissue did not differ in 652 
hearts perfused with Sunitinib compared to vehicle treated hearts.  653 
 654 
4.3.2. MKK7 655 
We assessed MKK7 expression level at both transcriptional and post-translational levels in 656 
hearts treated with Sunitinib with and without the upstream ASK1 inhibitor NQDI-1. There 657 
was a strong tendency for MKK7 mRNA expression to be decreased in Sunitinib perfused 658 
hearts compared to control, but without significance. The expression of MKK7 mRNA was 659 
increased significantly in Sunitinib and NQDI-1 co-treated hearts compared to Sunitinib 660 
perfused hearts, and NQDI-1 solo treatment did not alter the MKK7 mRNA expression 661 
compared to control hearts (Fig 3). The p-MKK7 level was significantly decreased in 662 
Sunitinib treated hearts when compared to control, and the p-MKK7 decrease is attenuated 663 
by NQDI-1 co-administration. The p-MKK7 levels are significantly decreased in Sunitinib and 664 
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NQDI-1 co-treatment and NQDI-1 solo-treatment hearts compared to control hearts (Fig 4B). 665 
We believe that this is the first study to investigate the expression of MKK7 after Sunitinib 666 
therapy. 667 
 668 
MKK7 has a vital role in protecting the heart from hypertrophic remodelling and 669 
cardiomyocytes apoptosis during stress and therefore the transition into heart failure 670 
(Mitchell et al. 2006). Studies by Liu et al. 2011 revealed the importance of MKK7 by 671 
demonstrating that deprivation of MKK7 in cardiomyocytes provokes heart failure in mice 672 
when exposed to pressure overload (Liu et al. 2011). In addition to this, it has been shown 673 
that inhibition and specific knockout of MKK7 increases the sensitivity of hepatocytes to 674 
tumour necrosis factor alpha-induced apoptosis (Jia et al. 2015). Treatment with Sunitinib in 675 
rat hearts in the current study down regulates both mRNA and phosphorylated protein levels 676 
of MKK7. These studies suggest an important role of MKK7 in the maintenance of heart 677 
homeostasis and expression of associated genes are important during cardiac hypertrophy 678 
and heart failure.  679 
 680 
MKK7 contains an ATP binding domain which could be inhibited by the ATP analogue, 681 
Sunitinib (Roskoski 2007; Shukla et al. 2009; Song et al. 2013). It is therefore possible that 682 
Sunitinib has an inhibitory effect on the MKK7/JNK signal transduction pathway. With 683 
reduced MKK7 activity demonstrating both an incline towards cardiomyocyte damage and a 684 
reversal of anti-tumour effects of chemotherapy, it would be interesting to assess both the 685 
changes in expression levels and levels of phosphorylated MKK7 during Sunitinib treatment 686 
affecting the heart in future studies. It may therefore be possible to identify a link between 687 
MKK7 expression and tyrosine kinase inhibitor-induced cardiotoxicity. 688 
 689 
Co-treatment of Sunitinib and NQDI-1 increases the level of p-MKK7 to levels compared to 690 
Sunitinib treated hearts, restoring them almost back to the p-MKK7 levels observed in 691 
control hearts. This could suggest that phosphorylated MKK7 is required to maintain at a 692 
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stable level to prevent damage to the heart. To illustrate this upregulation of transforming 693 
growth factor beta has been found in compensatory hypertrophy, myocardial remodelling 694 
and heart failure (Rosenkranz 2004). However, if MKK7 is removed entirely from the JNK 695 
pathway cardiomyocyte damage ensues (Liu et al. 2011). Tang et al. 2012 demonstrated 696 
that by causing an upregulation of MKK7 in hepatoma cells with the treatment with Alpinetin 697 
it was possible to arrest cells in the G0/G1 phase of the cell cycle. However, by inhibiting 698 
MKK7 the anti-tumour effect of the delta-opioid receptor agonist cis-diammined 699 
dichloridoplatinum was reversed (Tang et al. 2012). This suggests that by agonising MKK7 it 700 
may be possible to both enhance anti-cancer properties of chemotherapy agents, as well as 701 
limiting apoptosis as the cell cycle is arrested. 702 
 703 
4.3.3. JNK 704 
Administration of Sunitinib decreased the p-JNK levels significantly when compared to 705 
control hearts, and this decrease was abrogated with NQDI-1 co-treatment. Treatment with 706 
NQDI-1 however also decreased the p-MKK7 levels when compared to control perfused 707 
hearts (Fig 4C).  708 
 709 
Many JNK knock out models have been used to determine the role of JNK in the 710 
development of cardiac dysfunction. Kaiser et al. 2005 demonstrated the importance of JNK 711 
in ischemia-reperfusion injury. They showed that a reduction in JNK activity in the heart 712 
resulted in a reduced level of cardiac injury and cellular apoptosis. The same study 713 
demonstrated an increase in JNK activity by using mouse models overexpressing MKK7 in 714 
the heart, and this caused a significant protection against ischemia-reperfusion injury (Kaiser 715 
et al. 2005). This highlights the complexity of JNK signalling. In this study, a significant 716 
decrease in JNK phosphorylation was identified when hearts were treated with Sunitinib. In 717 
addition, NQDI-1 treatment had a tendency to increase in JNK phosphorylation. It has been 718 
established that a reduction in JNK activation is associated with cardiac hypertrophy and 719 
cardiovascular dysfunction (Pan et al. 2014). The reduction in JNK activation caused by the 720 
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treatment of Sunitinib could also explain the increased infarct size and irregularities found in 721 
the haemodynamic data.  722 
 723 
Our study contradicts some previous studies, for example Wang et al. 1998 investigated the 724 
role of MKK7 in cardiac hypertrophy in neonatal myocytes (Wang et al. 1998). Transgenic 725 
neonatal rat cardiomyocytes expressing wild type MKK7 and a constitutively active mutant of 726 
MKK7 were created. This study demonstrated JNK specific activation by MKK7 and showed 727 
the key role of the JNK pathway in cardiac hypertrophy as cells infected with the 728 
constitutively active form of MKK7 adopted characteristic features of myocardial stress 729 
(Wang et al. 1998).  730 
 731 
The study by Fenton et al. 2010 looked at the expression of JNK in papillary cancer cells 732 
with RET/PTC1 rearrangement treated with Sunitinib (Fenton et al. 2010). Sunitinib inhibited 733 
proliferation of these RET/PTC1 subcloned papillary cancer cells, and furthermore inhibited 734 
the JNK phosphorylation in the cytoplasm of the papillary cancer cells. In our study the 735 
expression of p-JNK levels in left ventricular coronary tissue was also reduced in hearts 736 
perfused with Sunitinib compared to vehicle treated hearts. 737 
 738 
In summary, Sunitinib administration resulted in significant reduction in p-ASK1, p-MKK7 and 739 
p-JNK levels, whilst NQDI-1 co-administration counteracted this increase. It is worth noting 740 
that MKK7 is activated through phosphorylation at a special site at the C-terminal kinase 741 
domain core called the "Domain for Versatile Docking" (DVD), which includes serine and 742 
threonine sites (Wang et al. 2007). Sunitinib does not not discriminate between inhibition of 743 
tyrosine kinases or serine-threonine kinases (Karaman et al. 2008). Therefore, Sunitinib 744 
might potentially inhibiting serine-threonine kinases, however, it is much more likely that 745 
Sunitinib inhibits tyrosine kinases as expected, resulting in the downstream inhibition of 746 
ASK1, which then results in a downstream inhibition of MKK7 and JNK. However, more 747 
detailed investigations into the pathway involvement are required to fully elucidate the 748 
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intracellular signalling pathways. In addition, the increase in p-ASK1, p-MKK7 and p-JNK 749 
levels that we observe in the presence of both Sunitinib and NQDI-1, when compared to 750 
Sunitinib perfused hearts, could be due to the fact that we only assessed the 751 
phosphorylation of ASK1 at Thr845, however, it is possible that NQDI-1 blocks both Ser83 and 752 
Thr845 of ASK1, and further investigations of phosphorylation activity at both sides could 753 
clarify this issue. This altered pattern in ASK1/MKK7/JNK pathway phosphorylation suggests 754 
that Sunitinib has a direct effect on part of the ASK1/MKK7/JNK pathway. 755 
 756 
4.4. The anti-cancer properties of Sunitinib were enhanced by NQDI-1 treatment 757 
It is well established that Sunitinib achieves anti-tumour effects by inhibiting tyrosine kinases, 758 
which have been over-expressed in cancer cells (Krause and Van Etten 2005). Sunitinib has 759 
previously been shown to directly inhibit the survival and proliferation of a variety of cancer 760 
cells, including leukaemia cells (Ilyas 2016).  761 
 762 
We demonstrated a dose dependant decline in the cell viability of HL60 cells when treated 763 
with Sunitinib (Fig 5A). This produced an IC50 value of 6.16 µM. Our results are in line with 764 
existing data on the anti-proliferative effect of Sunitinib on HL60 cells. Sunitinib has 765 
previously been shown to reduce the level of HL60 cell survival in a dose dependant manor 766 
using a cell-titre blue reagent proliferation assay. This produced an IC50 value of 5.7 µM after 767 
48 hrs of Sunitinib treatment (Ilyas 2016).  Another group performed an MTT assay on a 768 
variety of acute myelogenous leukaemia cell lines and found Sunitinib to have an IC50 values 769 
between 0.007-13 µM (Hu et al. 2008). 770 
 771 
To investigate the anti-proliferative effect of inhibition of the MKK7 pathway, HL60 cells were 772 
treated with Sunitinib in co-treatment with NQDI-1 and NQDI-1 alone (Fig 5A-B). NQDI-1 is a 773 
selective inhibitor for ASK1, the upstream regulator of MKK7. Previous studies have shown 774 
ASK1 to have a crucial role in a variety of organ systems. However, ASK1 has also been 775 
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shown to promote tumorigenesis in gastric cancer and promote the proliferation of cancer 776 
cells in skin cancer (Hayakawa et al. 2012; Iriyama et al. 2009).  777 
 778 
Inhibition of ASK1 with compound K811 has been shown to prevent cell proliferation in 779 
gastric cancer cell lines and reduce the size of xenograft tumours (Hayakawa et al. 2012). 780 
Recently, Luo et al. 2016, investigated the involvement of ASK1 during proliferation in 781 
pancreatic tumour cell line PANC-1 (Luo et al. 2016).  The knock-down of ASK1 in mice with 782 
pancreatic tumours reduced tumour growth, suggesting that ASK1 has an important role in 783 
pancreatic tumorigenesis. The same group also demonstrated a dose-dependent inhibition 784 
of the PANC-1 cell line when cells were treated with NQDI-1 at concentrations of 10 and 30 785 
µM. However, the inhibition of ASK1 did not increase levels of apoptosis.  786 
 787 
We have shown that increasing concentrations of NQDI-1 (0.2-200 µM) significantly reduce 788 
the level of viable HL60 cells at 100 and 200 µM. This could suggest that ASK1 is expressed 789 
at different levels in different cell types as a higher concentration was required in HL60 cells 790 
compared to PANC-1 cells. Interestingly, the increasing concentrations of Sunitinib with 2.5 791 
µM NQDI-1 enhanced the level of Sunitinib induced a reduction in HL60 cell proliferation. 792 
The reason for this is not yet clear and further investigation into this is required.  793 
 794 
As mentioned before NQDI-1 blocks FGFR-1 (Volynets et al. 2011). In cancer cells FGFR1 795 
inhibitors have shown to elicit direct anti-tumour effects. The FGFR-1 inhibitors being 796 
investigated in clinical trials for their anti-tumour qualities effecting various cancer types 797 
include AZD4547, BGJ398, Debio-1347 and dovitinib (Katoh 2016). The apoptotic effect of 798 
NQDI-1 we are observing in HL60 cells can therefore be a direct consequence of FGFR-1 799 
inhibition.  800 
 801 
In conclusion, our study demonstrates the potential of NQDI-1 as a valuable asset to cardiac 802 
injury through the ASK1/MKK7/JNK transduction pathway, which could potentially lead to 803 
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development of cardioprotective adjunct therapy during drug-induced cardiac injury. NQDI-1 804 
was observed to be cardioprotective as it reduced the Sunitinib-induced infarct size, and 805 
addition it increased the apoptotic effect of Sunitinib in HL60 cells. This could indicate that 806 
NQDI-1 - or an optimised derivative - could potentially be used as cardioprotective adjunct 807 
therapy in e.g. Sunitinib treated leukaemia patients, which would not only protect the 808 
patients’ hearts but also boost the anti-cancer abilities of Sunitinib.  809 
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Figure legends 821 
Figure 1: Infarct to whole heart ratio assessment. The hearts were drug perfused with 822 
Sunitinib and/or NQDI-1 for 125 min in an isolated Langendorff heart model. This establishes 823 
that Sunitinib-induced cardiotoxicity is reduced by ASK1 inhibitor NQDI-1. Groups: Control, 824 
Sunitinib (1 µM), Sunitinib (1 µM) and NQDI-1 (2.5 µM), and NQDI-1 (2.5 µM) (n=6 per 825 
group). Groups were assessed for statistical significance at each time point using one-way 826 
ANOVA. Control versus Sunitinib (***=P<0.001), Control versus Sunitinib+NQDI-1 827 
(**=P<0.01), Control versus NQDI-1 (*=P<0.05), or Sunitinib vs Sunitinib+NQDI-1 828 
(###=P<0.001). 829 
 830 
Figure 2: Cardiotoxicity linked microRNAs expression. The effect of Sunitinib (1 µM) and 831 
the co-administration of ASK1 inhibitor, NQDI-1 (2.5 µM), on the expression of cardiotoxicity 832 
linked microRNAs following 125 minute drug perfusion in an isolated heart Langendorff 833 
model. The qRT-PCR results are shown as the ratio of target microRNA normalised to U6 834 
with control group microRNA ratio set as 1 of microRNAs A) miR-1, B) miR-27a, C) miR-835 
133a and D) miR-133b. The ratio of target microRNA normalised to U6 is presented on a log 836 
scale. Groups: Control (n=6 for miR-1, miR-27a and miR-133a; n=5 for miR-133b), Sunitinib 837 
(1 µM) (n=6 for miR-1 and miR-27a; n=5 for miR-133a and miR-133b), Sunitinib (1 µM) and 838 
NQDI-1 (2.5 µM) (n=6 for miR-1, miR-27a, miR-133a and miR-133b), and NQDI-1 (2.5 µM) 839 
(n=4 for miR-1, miR-27a, miR-133a and miR-133b). Groups were assessed for statistical 840 
significance at each time point using one-way ANOVA. Control versus Sunitinib 841 
(***=P<0.001), Control versus Sunitinib+NQDI-1 (*=P<0.05, **=P<0.01), Control versus 842 
NQDI-1 (**=P<0.01, ***=P<0.001), or Sunitinib vs Sunitinib+NQDI-1 (#=p<0.05, 843 
###=P<0.001). 844 
 845 
Figure 3: MKK7 mRNA expression levels. The qRT-PCR assessment of MKK7 mRNA 846 
expression levels in an isolated heart Langendorff model. The qRT-PCR results are shown 847 
as the ratio of MKK7 mRNA normalised to GAPDH with control group ratio set as 1. Groups: 848 
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Control (n=5), Sunitinib (1 µM) (n=6), Sunitinib (1 µM) and NQDI-1 (2.5 µM) (n=3), and 849 
NQDI-1 (2.5 µM) (n=3). Groups were assessed for statistical significance at each time point 850 
using one-way ANOVA. Control versus Sunitinib, Control versus Sunitinib+NQDI-1, Control 851 
versus NQDI-1, or Sunitinib vs Sunitinib+NQDI-1 (#=p<0.05). 852 
 853 
Figure 4: ASK1/MKK7/JNK pathway western blot assessment. A) p-ASK1, B) p-MKK7, 854 
and C) p-JNK phosphorylation levels in an isolated heart Langendorff model. Sorbitol was 855 
included as a positive control in p-MKK7 Western blot analysis (n=4). Groups: Control (n=6 856 
for p-ASK1; n=4 for p-MKK7 and p-JNK), Sunitinib (1 µM) (n=5 for p-ASK1; n=4 for p-MKK7 857 
and p-JNK), Sunitinib (1 µM) and NQDI-1 (2.5 µM) (n=6 for p-ASK1; n=4 for p-MKK7 and p-858 
JNK) and NQDI-1 (2.5 µM) (n=5 for p-ASK1; n=4 for p-MKK7 and p-JNK). Groups were 859 
assessed for statistical significance at each time point using one-way ANOVA. Control 860 
versus Sunitinib (***=P<0.001), Control versus Sunitinib+NQDI-1 (*=p<0.05), Control versus 861 
NQDI-1 (**=P<0.01; ***=P<0.001), or Sunitinib vs Sunitinib+NQDI-1 (#=p<0.05; 862 
###=P<0.001). 863 
 864 
Figure 5: HL60 cell viability. HL60 cells (105 cells/ml) were incubated for 24 hours with 865 
control or with increasing concentrations of A) Sunitinib (0.1 – 10 μM) or Sunitinib (0.1 – 10 866 
μM) + NQDI-1 (2.5 µM) or B) NQDI-1 (0.2 µM – 200 μM). Groups were assessed for 867 
statistical significance at each time point using one-way ANOVA. Control versus Sunitinib 868 
(*=P<0.05 and ***=P<0.001), Control versus NQDI-1 (*=P<0.05 and ***=P<0.001), or 869 
Sunitinib vs Sunitinib+NQDI-1 (###=p<0.001).  870 
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Abstract  28 
The tyrosine kinase inhibitor Sunitinib is used to treat cancer and is linked to severe adverse 29 
cardiovascular events. Mitogen activated kinase kinase 7 (MKK7) is involved in the 30 
development of cardiac injury and is a component of the c-Jun N-terminal kinase (JNK) 31 
signal transduction pathway. Apoptosis signal-regulating kinase 1 (ASK1) is the upstream 32 
activator of MKK7 and is specifically inhibited by 2,7-dihydro-2,7-dioxo-3H-naphtho[1,2,3-33 
de]quinoline-1-carboxylic acid ethyl ester (NQDI-1). This study investigates the role of ASK1, 34 
MKK7 and JNK during Sunitinib-induced cardiotoxicity. 35 
 36 
Infarct size were measured in isolated male Sprague-Dawley rat Langendorff perfused 37 
hearts treated for 125 min with Sunitinib in the presence and absence of NQDI-1. Left 38 
ventricular cardiac tissue samples were analysed by qRT-PCR for MKK7 mRNA expression 39 
and cardiotoxicity associated microRNAs (miR-1, miR-27a, miR-133a and miR-133b) or 40 
Western blot analysis to measure ASK1/MKK7/JNK phosphorylation.  41 
  42 
Administration of Sunitinib (1 µM) during Langendorff perfusion resulted in increased infarct 43 
size, increased miR-133a expression, and decreased phosphorylation of the 44 
ASK1/MKK7/JNK pathway compared to control. Co-administration of NQDI-1 (2.5 µM) 45 
attenuated the increased Sunitinib-induced infarct size, reversed miR-133a expression and 46 
restored phosphorylated levels of ASK1/MKK7/JNK. These findings suggest that the 47 
ASK1/MKK7/JNK intracellular signalling pathway is important in Sunitinib-induced 48 
cardiotoxicity. The anti-cancer properties of Sunitinib were also assessed using the 3-(4,5-49 
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell viability assay.  Sunitinib 50 
significantly decreased the cell viability of human acute myeloid leukemia 60 cell line (HL60). 51 
The combination of Sunitinib (1 nM - 10 µM) with NQDI-1 (2.5 µM) enhanced the cancer-52 
fighting properties of Sunitinib. Investigations into the ASK1/MKK7/JNK transduction 53 
pathway could lead to development of cardioprotective adjunct therapy, which could prevent 54 
Sunitinib-induced cardiac injury. 55 
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 65 
1. Introduction  66 
The tyrosine kinase inhibitor Sunitinib is used in the treatment of renal cell carcinoma and in 67 
gastrointestinal stromal tumours (Faivre et al. 2007). The tyrosine kinase inhibitor Sunitinib is 68 
used in the treatment of many soft cell cancers (Faivre et al. 2007). Sunitinib prevents 69 
tumour cell survival and angiogenesis by inhibiting a variety of growth factor and cytokine 70 
receptors, including platelet derived growth factor receptors, vascular endothelial growth 71 
factor receptors and proto-oncogenes c-Kit and RET. However, Sunitinib unfortunately is 72 
also associated with a lack of kinase selectivity resulting in the cardiotoxic adverse effects 73 
(Force et al. 2007). In the clinic, Sunitinib causes QT prolongation (Bello et al. 2009),left 74 
ventricular dysfunction (Shah and Morganroth 2015) and heart failure (Ewer et al. 2014).  75 
These findings are consistent with many other successful chemotherapy agents linked with 76 
severe drug-induced cardiotoxicity (Hahn et al. 2014), including electrophysiological changes 77 
and left ventricular dysfunction which can cause heart failure in some patients (Aggarwal et 78 
al. 2013). Intracellular studies using animals have revealed that Sunitinib causes 79 
mitochondrial injury and cardiomyocyte apoptosis through an increase in caspase-9 and 80 
cytochrome C release in both mice and in cultured rat cardiomyocytes (Chu et al. 2007). 81 
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Other indicators of apoptosis, such as an increase in caspase-3/7, have also been detected 82 
after Sunitinib treatment in rat myocytes (Hasinoff et al. 2008). 83 
 84 
MKK7 is a member of the mitogen-activated protein kinase kinase super family, which allows 85 
the cell to respond to exogenous and endogenous stimuli (Foltz et al. 1998), and furthermore 86 
MKK7 has shown to demonstrate a key role in protecting the heart from hypertrophic 87 
remodelling, which occurs via cardiomyocyte apoptosis and heart failure (Liu et al. 2011). 88 
The MKK7 activation of JNK results in many cellular processes including: proliferation, 89 
differentiation and apoptosis (Chang and Karin 2001; Schramek et al. 2011; Sundarrajan et 90 
al. 2003), and JNK signalling is vital for the maintenance and organisation of the 91 
cytoskeleton and sarcomere structure in cardiomyocytes (Windak et al. 2013). Interestingly, 92 
Sunitinib is an ATP analogue and competitively inhibits the ATP binding domain of its target 93 
proteins (Roskoski 2007; Shukla et al. 2009). MKK7 also contains a highly conserved ATP 94 
binding domain (Song et al. 2013). It is possible that Sunitinib binds as a ligand in the MKK7 95 
ATP binding pocket, and thereby Sunitinib inhibits the MKK7/JNK transduction pathway, and 96 
as a result this could potentially cause myocardial injury. It is important to determine the 97 
relationship between MKK7 expression and Sunitinib induced cardiotoxicity by measuring 98 
the alteration of MKK7 mRNA and phosphorylated MKK7 levels in the presence of Sunitinib. 99 
Unravelling the relationship between Sunitinib and MKK7 could lead to a greater 100 
understanding of its off-target mechanism of action and lead to the improvement in the 101 
development of future drug discovery programmes or novel cardioprotective adjunct 102 
therapies. 103 
 104 
Short non-coding RNA microRNAs carry out the negative regulation of mRNA transcripts by 105 
repressing translation (Bagga et al. 2005). Specific microRNAs expression patterns have 106 
been linked to cardiomyocyte differentiation and in response to stress (Babiarz et al. 2012) 107 
and have also been shown to be differentially expressed during the development of heart 108 
failure (Thum et al. 2007). The microRNAs miR-1, miR-27a, miR-133a and miR-133b 109 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 
 
5 
 
produce differential expression patterns during the progression of heart failure (Akat et al. 110 
2014; Tijsen et al. 2012). It is important to identify microRNA expression profiles in response 111 
to drug-induced cardiotoxicity as similar patterns in microRNA expression to those identified 112 
during heart failure may indicate the early onset of cardiotoxicity at a molecular level.  113 
 114 
As MKK7 has no direct inhibitor, we have chosen to look at the upstream kinase ASK1 115 
linked to MKK7 activation (Ichijo et al. 1997). ASK1 is activated in response to oxidative 116 
stress-induced cardiac vascular endothelial growth factor suppression in the heart (Nako et 117 
al. 2012). Izumiya et al. 2003 used ASK1 deficient transgenic mice to assess the role of 118 
ASK1 in angiotensin II induced hypertension and cardiac hypertrophy. Both the wild type and 119 
ASK1 deficient mice developed hypertension when stimulated with angiotensin II, however, 120 
the ASK1 deficient mice lacked cardiac hypertrophy and remodelling and activation of ASK1, 121 
p38 and JNK was severely attenuated, thus emphasising the importance of ASK1 in cardiac 122 
hypertrophy and remodelling signalling (Izumiya et al. 2003). ASK1 is selectively inhibited by 123 
NQDI-1 with high specificity with a Ki of 500nM and IC50 of 3µM (Volynets et al. 2011), 124 
however, as this is a relatively new drug, a complete pharmacological profile has not yet 125 
been fully characterised. ASK1 inhibition has previously been shown to offer protection 126 
against ischemia reperfusion injury (Toldo et al. 2012) and has also been shown to suppress 127 
the progression of ventricular remodelling and fibrosis in hamsters expressing severe 128 
cardiomyopathy phenotypes (Hikoso et al. 2007). These findings highlight the potential of 129 
NQDI-1 as a valuable asset to inhibit cardiac injury via the ASK1/MKK7/JNK pathway. 130 
 131 
This novel study investigated the involvement of the ASK1/MKK7/JNK pathway in the 132 
Sunitinib-induced cardiotoxicity via the assessment of cardiac function and infarct in 133 
conjunction with relevant intracellular signalling mediators. Furthermore, we assessed the 134 
anti-cancer properties of Sunitinib and determined whether co-administration of Sunitinib 135 
with NQDI-1 affected the anti-cancer/apoptotic effect of Sunitinib in HL60 cells.  136 
 137 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 
 
6 
 
2. Materials and Methods  138 
2.1. Main reagents and kits 139 
Sunitinib malate and NQDI-1 were purchased from Sigma Aldrich (UK). Both drugs were 140 
dissolved in dimethyl sulphoxide (DMSO) and stored at -20 °C. Krebs perfusate salts were 141 
from either VWR International (UK) or Fisher Scientific (UK). Total ASK1 (Catalogue no 142 
ab131506) was purchased from Abcam (UK). Phospho-ASK1 (Thr 845) (Catalogue no 143 
3765S), Phospho-MKK7 (Ser271/Thr275) (Catalogue no 4171S), Total MKK7 (Catalogue no 144 
4172S), Phospho-SAPK/JNK (Thr183/Tyr185) (Catalogue no 9251), Total SAPK/JNK rabbit 145 
mAb antibody (Catalogue no 9252), anti-rabbit IgG, HRP-linked antibody and anti-biotin, 146 
HRP-linked antibody were purchased from Cell signalling technologies (UK). All the 147 
primary antibodies were from a rabbit host, and MKK7 and JNK were monoclonal antibodies, 148 
whereas ASK1 was polyclonal (all antibodies were validated by the manufacturers). The 149 
Ambion MicroPoly(A)Puris kit, Ambion mirVana miRNA Isolation Kit and Reverse 150 
Transcription Kit were from Life Technologies (USA). The mRNA primers and the Applied 151 
Biosystems primers assays (U6, rno-miR-1, hsa-miR-27a, hsa-miR-133a, and hsa-miR-152 
133b) were purchased from Invitrogen (UK).The iTaq Universal SYBR Green Supermix was 153 
purchased from BioRad (UK). The HL60 cell line were obtained from European Collection of 154 
Cell Culture (UK) (catalogue no. 98070106). 155 
 156 
2.2. Animals  157 
Adult male Sprague-Dawley rats (300-350 g in body weight); were purchased from Charles 158 
River UK Ltd (UK) and housed suitably. They received humane care and had free access to 159 
standard diet according to the Guide for the Care and Use of Laboratory Animals published 160 
by the US National Institute of Health (NIH Publication No. 85-23, revised 1996). Animals 161 
were selected at random for all treatment groups and the collected tissue was blinded for 162 
infarct size assessment. The experiments were performed following approval of the protocol 163 
by the Coventry University Ethics Committee. All efforts were made to minimise animal 164 
suffering and to reduce the number of animals used in the experiments. Rats were sacrificed 165 
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by cervical dislocation (Schedule 1 Home Office procedure). A total of 80 animals were used 166 
for this study and the data from 68 rats were included, while data from 12 rats were excluded 167 
from analysis due to the established haemodynamic exclusion criteria. No animals were 168 
culled due to ill health.  A total of 16 animals were included for Langendorff perfusion 169 
experiments per main groups (Control, Sunitinib, Sunitinib+NQDI-1, and NQDI-1, where 6 of 170 
the animals were used for measurement of the area of infarct and the area of risk and the 171 
left ventricular tissue from another 10 animals was used for real time PCR and Western blot 172 
analysis). Furthermore, an additional 4 animals were used for Langendorff perfusion 173 
experiments with Sorbitol as a positive control for p-MKK7 Western blot analysis. 174 
 175 
2.3. Langendorff perfusion model  176 
The hearts were rapidly excised after the rats were culled and placed into ice-cold Krebs 177 
Henseleit buffer (118.5 mM NaCl, 25 mM NaHCO3, 4.8 mM KCl, 1.2 mM MgSO4, 1.2 mM 178 
KH2PO4, 1.7 mM CaCl2, and 12 mM glucose, pH7.4). Each Langendorff study was 179 
conducted using the protocol for naïve Langendorff studies (Gharanei et al. 2013). The 180 
hearts were mounted onto the Langendorff system and retrogradely perfused with Krebs 181 
Henseleit buffer. The pH of the Krebs Henseleit buffer was maintained at 7.4 by gassing 182 
continuously with 95 % O2 and 5 % CO2 and maintained at 37 ± 0.5 °C using a water-183 
jacketed organ chamber. Each Langendorff experiment was carried out for 145 minutes: a 184 
20 minute stabilisation period and 125 minutes of drug or vehicle perfusion in normoxic 185 
conditions. Hearts were included in the study with a CF between 3.5-12.0 ml/g (weight of the 186 
rat heart) during the stabilisation period. Sunitinib malate (1 µM) was administered 187 
throughout the perfusion period in the presence or absence of NQDI-1 (2.5 µM).  188 
   189 
The clinically relevant dose of 1 µM Sunitinib was chosen in line with previous studies by 190 
(Henderson et al. 2013). Additionally, it has been reported that the plasma concentration of 191 
Sunitinib has a Cmax in the rage of 0.5–1.4µM (Doherty et al. 2013).  While, the dose of 2.5 192 
µM NQDI-1 was chosen following a thorough literature review (Eaton et al. 2014; Song et al. 193 
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2015; Volynets et al. 2011). NQDI-1 is not yet used in the clinic, therefore a clinically relevant 194 
dose has not been reported. 195 
 196 
Langendorff perfused hearts treated with vehicle were analysed as the control group. The 197 
hearts were then weighed and either stored at -20 °C for 2,3,5-triphenyl-2H-tetrazolium 198 
chloride (TTC) staining or the left ventricular tissue was dissected free and immersed in 199 
RNAlater from Ambion (USA) for qRT-PCR or snap frozen by liquid nitrogen for Western blot 200 
analysis. 201 
 202 
2.4. Infarct size analysis  203 
Frozen whole hearts were sliced into approximately 2 mm thick transverse sections and 204 
incubated in 0.1 % TTC solution in phosphate buffer (2 ml of 100 mM NaH2PO4.2H2O and 8 205 
ml of 100 mM NaH2PO4) at 37 °C for 15 minutes and fixed in 10% formaldehyde (Fisher 206 
Scientific, UK) for 4 hours. The risk zone and infarct areas were traced onto acetate sheets.  207 
The tissue at risk stained red and infarct tissue appeared pale. The acetate sheet was 208 
scanned and ImageTool from UTHSCSA (USA) software was used to measure the area of 209 
infarct and the area of risk. A ratio of infarct to risk size was calculated as a percentage for 210 
each slice. An average was taken of all of the slices from each heart to give the percentage 211 
infarct size of the whole heart. The mean of infarct to risk ratio for each treatment group and 212 
the mean ± SEM was plotted as a bar chart. The infarct size determination was randomised 213 
and blinded. 214 
 215 
2.5. Analysis of microRNA expression profiles 216 
The microRNA was isolated from left ventricular tissue using the mirVana™ miRNA Isolation 217 
Kit from Ambion (UK). The microRNA quantity and quality was measured by NanoDrop from 218 
Nanoid Technology (USA).  A total of 500 ng microRNA was reverse transcribed into cDNA 219 
using primers specific for housekeeping reference RNA U6 snRNA and target microRNAs: 220 
hsa-miR-155, hsa-miR-15a, hsa-miR-16-1, rno-miR-1, hsa-miR-27a, hsa-miR-133a or hsa-221 
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miR-133b (please note all human hsa-miR assays are compatible with rat samples) from 222 
Applied Biosystems (USA) using the MicroRNA Reverse Transcription Kit from Applied 223 
Biosystems (USA) according to the manufacturer's instructions. The reverse transcription 224 
quantitative PCR reaction was performed with the following setup: 16 °C for 30 min, 42°C for 225 
30 min and 85 °C for 5 min and ∞ at 4°C. The qRT-PCR was performed using the TaqMan 226 
Universal PCR Master Mix II (no UNG) from Applied Biosystems (USA) protocol on the 7500 227 
HT Real Time PCR sequence detection system from Applied Biosystems (USA). A 20μl 228 
reaction mixture containing 100 ng cDNA, specific primer assays mentioned above from 229 
Applied Biosystems (USA) and the TaqMan Universal PCR Master Mix was used in the qRT-230 
PCR reaction in triplicates.  A non-template control was included in all experiments. The real 231 
time PCR reaction was performed using the program: 1) 2 minutes at 50°C, 2) 10 minutes at 232 
95°C, 3) 15 seconds at 95°C, 4) 1 minute at 60°C. Steps 3) and 4) were repeated 40 times. 233 
 234 
Analysis of qRT-PCR data of microRNAs were performed using the Ct values for U6 snRNA 235 
as reference for the comparison of the relative amount of microRNAs (rno-miR-1, hsa-miR-236 
27a, hsa-miR-133a and hsa-miR-133b). The values of each of the microRNAs were 237 
calculated to compare their ratios. The formula used was X0/R0=2
CTR-CTX, where X0 is the 238 
original amount of target microRNA, R0 is the original amount of U6 snRNA, CTR is the CT 239 
value for U6 snRNA, and CTX is the CT value for the target microRNAs (rno-miR-1, hsa-240 
miR-27a, hsa-miR-133a and hsa-miR-133b) (Sandhu et al. 2010). Averages of the Ct values 241 
for each sample group (Control and Sunitinib treated hearts) and each individual primer set 242 
were calculated and bar charts were plotted with mean ± SEM.  The mean of the control 243 
group was set as 1 for all microRNAs.  244 
 245 
2.6. Measurement of MKK7 mRNA expression 246 
Total mRNA was extracted from left ventricular tissue using The Ambion MicroPoly(A)Purist 247 
kit from Ambion (USA). Extracted mRNA was processed directly to cDNA by reverse 248 
transcription using Reverse Transcription Kit from Applied Biosystems (USA) with the 249 
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respective primers for MKK7 (MKK7 forward primer: CCCCGTAAAATCACAAAGAAAATCC 250 
and MKK7 reverse primer: GGCGGACACACACTCATAAAACAGA) and GAPDH (GAPDH 251 
Forward primer: GAACGGGAAGCTCACTGG and GAPDH Reverse primer: 252 
GCCTGCTTCACCACCTTCT) according to the instructions from the manufacturer Invitrogen 253 
(UK). The reverse transcription PCR reaction was performed with the following setup: 16 °C 254 
for 30 minutes, 42°C for 30 minutes and 85 °C for 5 minutes. The qRT-PCR reactions were 255 
performed with the iTaq Universal SYBR Green Supermix from BioRad (UK), GAPDH and 256 
MKK7 mRNA primer sets on the 7500 HT Real Time PCR machine from Applied Biosystems 257 
(USA) using the program: 1) 2 minutes at 50°C, 2) 10 minutes at 95°C, 3) 15 seconds at 258 
95°C, 4) 1 minute at 60°C. Steps 3) and 4) were repeated 40 times. 259 
 260 
Analysis of qRT-PCR data of MKK7 mRNA were performed using the Ct values for GAPDH 261 
mRNA as reference for the comparison of the relative amount of MKK7 mRNA. The value of 262 
mRNA was calculated to compare the ratios using the formula X0/R0=2
CTR-CTX, where X0 is 263 
the original amount of target mRNA, R0 is the original amount of GAPDH mRNA, CTR is the 264 
CT value for GAPDH mRNA, and CTX is the CT value for the MKK7 mRNA (Sandhu et al. 265 
2010). Averages of the Ct values for each sample group (control and Sunitinib treated 266 
hearts) and each individual primer set were calculated and bar charts were plotted with 267 
mean ± SEM.  The mean of the control group was set as 1 for the MKK7 mRNA.  268 
 269 
2.7. Western blot detection of ASK1, MKK7 and JNK 270 
A total 45-55 mg of the frozen left ventricular tissue was lysed in lysis buffer (NaCl 0.1 M, 271 
Tris base 10 µM, EDTA 1 mM, sodium pyrophosphate 2 mM, NaF 2 mM, β-glycaophosphate 272 
2 mM, 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride (0.1 mg/ml, 1/1.5 of protease 273 
cocktail tablet) using a IKA Overtechnical T25homogeniser at 11,000 RPM. The 274 
supernatants were measured for protein content using NanoDrop from Nanoid Technology 275 
(USA). Then 80 µg of protein was loaded to 4–15 % Mini-Protean TGX Gel from BioRad 276 
(UK) and separated at 200 V for 60 minutes. After separation, the proteins were transferred 277 
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to the Bond-P polyvinylidene difluoride membrane from BioRad (UK) by using the Trans-Blot 278 
Turbo transfer system from BioRad (UK) and probed for the phosphorylated forms 279 
Phospho(Thr845)-ASK1 (p-ASK1), Phospho(Ser271/Thr275)-MKK7 (p-MKK7) and 280 
Phospho(Thr183/Tyr185) -SAPK/JNK (p-JNK), and total forms of ASK1(Thr845), 281 
MKK7(Ser271/Thr275) and JNK(Thr183/Tyr185). The p-MKK7 and p-JNK blots were stripped by 282 
boiling and the PVDF membrane was used for total MKK7 and total JNK analysis, 283 
respectively. According to recommendations from Cell signalling technologies (UK) total 284 
ASK1 analysis had to be performed on a separate Western blot, as the stripping procedure 285 
would remove total ASK1 protein. The relative changes in the p-ASK1, p-MKK7 and p-JNK 286 
protein levels were measured and corrected for differences in protein loading as established 287 
by probing for total ASK1, MKK7 and JNK respectively. 288 
 289 
For Western blot analysis phosphorylated antibody levels were normalised to total antibody 290 
levels in order to correlate for unequal loading of protein and differential blot transfer and to 291 
identify the level of active vs inactive protein levels. Results were expressed as a percentage 292 
of the density of phosphorylated protein relative to the density of total protein using Image 293 
Lab 4.1 from BioRad (UK). The phosphorylated antibody levels determination was 294 
randomised and blinded.  295 
 296 
2.8. MTT assay assessment of HL60 cell viability in the presence of Sunitinib with and 297 
without NQDI-1 298 
The HL60 cell line were maintained in in RPMI 1640 medium supplemented with L-299 
Glutamine (2 mM) and 10 % heat-inactivated fetal bovine serum and antibiotics mix at 37 °C 300 
in a humidiﬁed incubator under 5 % CO2/95 % air. Cells were split in a 1:5 ratio every 2-3 301 
days. Cells were incubated with Control, increasing concentrations of Sunitinib (1nM – 10 302 
μM), Sunitinib (0.1 – 10 μM) + NQDI-1 (2.5 µM), or increasing concentrations of NQDI-1 303 
(0.2-200 µM) for 24 h. Both Sunitinib and NQDI-1 were dissolved in DMSO. The DMSO 304 
concentration was < 0.05 % (v/v) during the in vitro studies.  305 
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 306 
Cells were plated at a cell density of 105 cells/ml in 96-well plates and the above indicated 307 
concentration of the drug was added. The plate was then incubated at 37°C for 24hrs. After 308 
drug incubation, 50 µl of MTT solution (5 mg MTT/ml H2O) was added and the cells were 309 
incubated for a further 24 h. Next, 50 µl of DMSO was added to each well and mixed by 310 
pipetting to release reduced MTT crystals from the cells. Relative cell viability was obtained 311 
by scanning with an ELISA reader (Anthos Labtech AR 2001 Multiplate Reader, Anthos 312 
Labtec Instruments, Austria) with a 490 nm ﬁlter. Results were expressed as a percentage of 313 
viable cells relative to untreated cells/control. Experiments were performed in triplicates and 314 
repeated ≥ 3 times. 315 
 316 
2.9. Statistical analysis 317 
Results are presented as mean ± standard error of the mean (SEM). Significance of all data 318 
sets was measured by one-way ANOVA analysis with the Tukey post hoc test using the 319 
Matlab prism program. The following groups were compared during ANOVA analysis: 320 
Control versus Sunitinib, Control versus Sunitinib and NQDI-1, Control versus NQDI-1 (all 321 
statistically significant data compared to control marked with *), and Sunitinib versus 322 
Sunitinib and NQDI-1 (all statistically significant data compared to Sunitinib marked with #). 323 
Control versus Sunitinib (red), Control versus versus Sunitinib and NQDI-1 (green), Control 324 
versus NQDI-1 (blue) (all statistically significant data compared to control marked with *), 325 
and Sunitinib versus Sunitinib and NQDI-1 (all statistically significant data compared to 326 
Sunitinib marked with a purple $). For MKK7 mRNA some data was evaluated by using 327 
student’s t-test. P-values <0.05 were considered statistically significant. 328 
 329 
3. Results 330 
3.1. Sunitinib treatment induces cardiac injury  331 
The effect of Sunitinib (1µM) administration on myocardial infarction development was 332 
investigated by TTC staining. The hearts were stabilised for a period of 20 minutes, followed 333 
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by 125 minutes of drug perfusion. Administration of Sunitinib (1µM) for 125 minutes resulted 334 
in a significant increase in infarct size compared with non-treated controls (Control: 7.81 ± 335 
1.16 %; Sunitinib: 41.02 ± 1.23 %, p<0.001) (Fig 1). This demonstrated that Sunitinib 336 
treatment of the Langendorff perfused hearts results in a drastic increase in cardiac injury. 337 
The infarct was globally distributed in all groups investigated in this study (i.e. Control, 338 
Sunitinib ± NQDI-1, and NQDI-1). 339 
 340 
3.2. Sunitinib and NQDI-1 co-treatment alleviate cardiac injury  341 
The effect of ASK1 inhibition by NQDI-1 on cardiac function and infarction was investigated.  342 
Co-administration of Sunitinib (1 µM) with NQDI-1 (2.5 µM) significantly decreased infarct 343 
size compared to Sunitinib treated hearts (Sunitinib: 41.02 ± 1.23 %; Sunitinib + NQDI-1: 344 
17.54 ± 2.97 %, p<0.001). However, administration of NQDI-1 alone for 125 minutes of 345 
perfusion significantly increased infarct size compared with control hearts (Control: 7.81 ± 346 
1.16 %; NQDI-1: 16.68 ± 2.66 %, p<0.05) (Fig 1). 347 
 348 
3.3. Sunitinib treatment modulates expression of microRNAs involved in cardiac 349 
injury 350 
The expression of cardiac injury specific microRNAs during Sunitinib-induced cardiotoxicity 351 
was determined by qRT-PCR assessment. The microRNAs miR-1, miR-27a, miR-133a and 352 
miR-133b have been shown to produce differential expression patterns during the 353 
progression of heart failure. The ratio of target microRNA normalised to U6 was set to 1 in 354 
the control group for easier comparison of microRNA ratio values between the various drug 355 
therapy groups.  There was a significant increase in miR-133a when hearts were perfused 356 
with Sunitinib (1 µM) compared to control hearts (Ratio of target microRNA normalised to U6 357 
in Sunitinib treated hearts: miR-133a: 535.78 ± 61.27, p<0.001). Co-administration of NQDI-358 
1 (2.5 µM) along with Sunitinib reversed this miR-133a expression trend by decreasing the 359 
miR-133a expression when compared to Sunitinib perfused hearts (Ratio of target microRNA 360 
normalised to U6 in Sunitinib and NQDI-1 treated hearts: miR-133a: 52.76 ± 28.30, 361 
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p<0.001). Hearts perfused with NQDI-1 alone showed an increase in miR-1, miR-27a and 362 
miR-133b expression compared to control hearts (Ratio of target microRNA normalised to 363 
U6 in NQDI-1 treated hearts: miR-1: 32.33 ± 16.47, p<0.01; miR-27a: 11.27 ± 2.86, p<0.001; 364 
miR-133b: 167.85 ± 58.13, p<0.001). The expression of miR-1, miR-27a, miR-133a and 365 
miR-133b was increased in the Sunitinib and NQDI-1 co-treated hearts when compared to 366 
Sunitinib perfused hearts (miR-1: p<0.05; miR-27a: p<0.001; miR-133a: p<0.001; miR-133b: 367 
p<0.05). (Fig 2 A-D). 368 
 369 
The results from the microRNA qRT-PCR analysis show there is a similar expression pattern 370 
for miR-1, miR-27 and miR-133b, while miR-133a has its own pattern. This indicates that the 371 
cardiac injury induced by Sunitinib, which is alleviated by the ASK1 inhibitor NQDI-1, triggers 372 
a complex alteration of these cardiac injury microRNAs. Further studies looking at the 373 
altered expression profiles for these cardiac injury microRNAs have to be undertaken in 374 
order to clarify the expression patterns. This indicates a complex alteration of these cardiac 375 
injury microRNAs by Sunitinib and ASK1 specific inhibitor, NQDI-1. This indicates an 376 
interaction between the ASK1/MKK7 pathway and Sunitinib in respect to expression of 377 
cardiotoxicity linked microRNAs during cardiac injury. 378 
 379 
3.4. MKK7 mRNA expression profile is altered by ASK1 inhibitor NQDI-1 380 
As MKK7 contains an ATP binding domain (Song et al. 2013) and Sunitinib is an ATP 381 
analogue and competitively inhibits the ATP binding domain of its target proteins (Roskoski 382 
2007; Shukla et al. 2009). We therefore wanted to investigate the interaction between 383 
Sunitinib and MKK7, and question whether Sunitinib could bind as a ligand in the ATP 384 
binding pocket of MKK7. This would determine if Sunitinib might potentially have an 385 
inhibitory effect on the MKK7/JNK pathway. The relationship between MKK7 expression and 386 
Sunitinib-induced cardiotoxicity was assessing on transcriptional level by MKK7 mRNA qRT-387 
PCR analysis on Sunitinib (1 µM) perfused hearts, and the interaction by ASK1 specific 388 
inhibitor NQDI-1 was detected to highlight if any interaction between ASK1/MKK7 and 389 
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Sunitinib-induced alteration of MKK7 transcription due to cardiac injury was observed to 390 
impact on mRNA levels.  The ratio of MKK7 mRNA normalised to GAPDH was set to 1 in the 391 
control group for easier comparison of GAPDH normalised MKK7 mRNA values between the 392 
various drug therapy groups. The qRT-PCR analysis of MKK7 mRNA revealed that co-393 
administration of NQDI-1with Sunitinib caused a significant increase in MKK7 mRNA 394 
expression compared to Sunitinib treatment alone (p<0.01) (Ratio of MKK7 mRNA 395 
normalised to GAPDH. Sunitinib: 0.12 ± 0.03; Sunitinib + NQDI-1: 1.18 ± 0.65) (Fig 3). The 396 
decrease in MKK7 mRNA observed in the Sunitinib (1 µM) perfused hearts compared to 397 
control hearts was not significant, but a clear trend was observed. If the data from groups 398 
control and Sunitinib were compared using a Student’s t-test the decline in MKK7 mRNA in 399 
Sunitinib treated hearts was statistically significant with p=0.0043. 400 
 401 
These MKK7 mRNA qRT-PCR results clearly demonstrate that Sunitinib treatment shows a 402 
tendency to decrease the MKK7 mRNA, and co-administration of ASK1 specific inhibitor 403 
NQDI-1 restores the MKK7 mRNA level observed in control treated heart. This could indicate 404 
a complex regulation system where Sunitinib-induced cardiac injury in directly linked with the 405 
ability of Sunitinib to reduced MKK7 expression at transcriptional level, which is counteracted 406 
by the ASK1 specific inhibitor NQDI-1. 407 
 408 
3.5. ASK1/MKK7/JNK pathway is involved in Sunitinib-induced cardiotoxicity 409 
As explained in the previous MKK7 mRNA results section we wanted to investigate the 410 
interaction between Sunitinib and MKK7, as they both interact via the ATP binding pocket. 411 
The key question being if Sunitinib can bind as a ligand in the ATP binding pocket of MKK7 412 
and if Sunitinib is able to block the MKK7/JNK pathway. Here we investigate the role of 413 
cardiotoxic Sunitinib therapy on the ASK1/MKK7/JNK pathway phosphorylation and how the 414 
interaction with the cardioprotective ASK1 specific agent NQDI-1 effects the 415 
ASK1/MKK7/JNK pathway phosphorylation. Following Langendorff perfusion of Sunitinib and 416 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 
 
16 
 
NQDI-1, p-ASK1, p-MKK7 and p-JNK levels were measured in the left ventricular tissue of 417 
the hearts by Western blot analysis.  418 
 419 
Western blot analysis showed that Sunitinib treatment decreased p-ASK1, p-MKK7 and p-420 
JNK levels significantly when compared to control (density of phosphorylated protein 421 
normalised to total protein:  p-ASK1: Control: 389.43 ± 4.18 and Sunitinib: 16.47 ± 3.56, 422 
p<0.001; p-MKK7: Control: 55.60 ± 4.86 and Sunitinib: 23.66 ± 4.53, p<0.001; p-JNK:  423 
Control: 43.66 ± 2.82 and Sunitinib: 22.52 ± 2.74, p<0.001). Co-administration with NQDI-1 424 
increased the p-ASK1, p-MKK7 and p-JNK levels, and these were statistically significantly 425 
elevated when compared to heart treated with Sunitinib monotherapy  Co-administration with 426 
NQDI-1 restored the decrease in p-ASK1, p-MKK7 and p-JNK levels and increased them 427 
back to control levels (density of phosphorylated protein normalised to total protein: p-ASK1: 428 
Sunitinib + NQDI-1: 51.17 ± 3.66, p<0.001; p-MKK7: Sunitinib + NQDI-1: 38.11 ± 1.87, 429 
p<0.05; p-JNK: 48.95 ± 2.76, p<0.001). The p-ASK1, p-MKK7 and p-JNK levels were 430 
decreased in NQDI-1 treated hearts compared to control hearts (density of phosphorylated 431 
protein normalised to total protein: p-ASK1: NQDI-1: 20.56 ±1.99, p<0.01; p-MKK7: NQDI-1: 432 
18.40 ± 2.98, p<0.001; p-JNK: 28.78 ± 3.03, p<0.01) (Fig 4A-C).  433 
  434 
These Western blot results show that Sunitinib decreased the phosphorylation of the 435 
ASK1/MKK7/JNK pathway. The fact that Sunitinib was able to show a strong tendency of 436 
decreasing the MKK7 mRNA highlights that the decreased MKK7 phosphorylation is 437 
regulated at the transcriptional level, which is then affecting the post-transcriptional MKK7 438 
phosphorylation levels. However, interestingly the cardiotoxic Sunitinib is having an inhibiting 439 
effect throughout all three parts of the ASK1/MKK7/JNK pathway. Co-administration of 440 
NQDI-1 is counteracting the Sunitinib inhibiting effect on the phosphorylation level 441 
throughout the ASK1/MKK7/JNK pathway. These results show a clear indication of Sunitinib 442 
interacting with ASK1, MKK7 and JNK at post-translational level and MKK7 gene expression 443 
at pre-transcriptional level.  444 
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 445 
3.6. Cancer cell viability in response to Sunitinib with and without NQDI-1 446 
The effect of Sunitinib on cell viability was examined in HL60 cells. The HL60 cells were 447 
treated with Sunitinib for 24 hrs and then the level of mitochondrial metabolic-activity 448 
inhibition was measured with the MTT assay. Sunitinib showed a pronounced decrease in 449 
metabolic activity and a dose-dependent decrease in cell viability (Fig 5A). In particular, 450 
Sunitinib significantly reduces cell viability at 1 nM (82.62 ± 6.55 %, p<0.05), 0.1 µM (85.94 ± 451 
3.80 %, p<0.05), 0.5 µM (83.94 ± 3.86 %, p<0.05), 1 µM (77.28 ± 6.58 %, p<0.05), 5 µM 452 
(58.61 ± 4.44 % p<0.001) and 10 µM (47.14 ± 6.77 %, p<0.001) concentrations of Sunitinib. 453 
The IC50 value was 6.16 µM. All the concentrations of Sunitinib in the absence and presence 454 
of NQDI-1 used during this study produced significant reductions in HL60 cell viability 455 
compared to vehicle treatment. 456 
 457 
The co-administration of NQDI-1 (2.5 µM) to increasing concentrations of Sunitinib (1 nM - 458 
10 µM) enhanced the inhibition of mitochondrial metabolism shown by Sunitinib (Fig 5A). 459 
Specifically, co-treatment of Sunitinib with NQDI-1 reduced cell viability at 1 µM (59.58 ± 460 
6.30 %, p<0.001), 5 µM (36.62 ± 6.52 %, p<0.001) and 10 µM (15.10 ± 2.31 %, p< 0.001) 461 
concentrations of Sunitinib compared to Sunitinib alone. The IC50 value for Sunitinib plus 462 
NQDI-1 was 1.76 µM. 463 
 464 
Interestingly, increasing concentrations of NQDI-1 alone (0.2-200 µM) only significantly 465 
reduced cell viability at very high concentrations. Reductions in cell viability were significant 466 
at 100 µM (55.44 ± 12.39 %, p<0.05), 200 µM (33.15± 9.67 %, p<0.001) (Fig 5B). The IC50 467 
value for NQDI-1 produced by the MTT assay was 130.8 µM. 468 
 469 
4. Discussion  470 
4.1. Involvement of ASK1/MKK7/JNK in Sunitinib-induced cardiotoxicity  471 
The occurrence heart failure associated with anti-cancer treatment has been investigated 472 
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extensively (Khakoo et al. 2008), however, the underlying mechanism of cardiotoxicity is still 473 
unclear. Determining cellular pathways involved in Sunitinib-induced cardiotoxicity could help 474 
to develop therapies which could prevent the potential development of heart failure 475 
associated with Sunitinib treatment. 476 
 477 
Data presented in this study confirms that Sunitinib causes drug-induced myocardial injury 478 
via an increase in infarct size (Fig 1). We observed that infarct size increased from ~ 8 % in 479 
Control hearts to ~ 41 % in hearts perfused with Sunitinib. This observation is in accordance 480 
with our previous study, where we investigated the involvement of A3 adenosine receptor 481 
activation during Sunitinib induced cardiotoxicity in perfused rat hearts (Sandhu et al. 2017). 482 
Also, the injury induced by Sunitinib administration is very similar to ischemia/reperfusion 483 
injury rats investigated by the same Langendorff model (Gharanei et al. 2013). The Control 484 
rat hearts do suffer from minor infarct injury during the brief period it takes from sacrificing 485 
the animal and perfusing the heart with the Krebs buffer during the Langendorff model. This 486 
insult accounts for the ~ 8 % infarct size we observe in Control hearts. A dose of 1 µM 487 
Sunitinib increased the infarct to ~ 41 % in perfused heart, and this steady state blood 488 
concentration of Sunitinib has been found in patients treated with Sunitinib (Henderson et al. 489 
2013). As the rat hearts are physically much smaller than human hearts, the rat hearts may 490 
have been more sensitive to the adverse effect of Sunitinib administration at the clinically 491 
relevant dose of 1 µM.  492 
 493 
Other animal studies investigating Sunitinib-induced cardiotoxicity were linked to a significant 494 
decrease in left ventricular function (Henderson et al. 2013; Mooney et al. 2015), and 495 
interestingly left ventricular dysfunction has also been identified in patients undergoing 496 
Sunitinib chemotherapy (Di Lorenzo et al. 2009). Data presented in this study confirms that 497 
Sunitinib causes drug-induced myocardial injury via an increase in infarct size (Fig 1). These 498 
observations are in accordance with other studies investigating Sunitinib-induced 499 
cardiotoxicity linked with a significant decrease in left ventricular function in animals 500 
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(Henderson et al. 2013; Mooney et al. 2015), and left ventricular dysfunction has also been 501 
identified in patients undergoing Sunitinib chemotherapy (Di Lorenzo et al. 2009). Also, 502 
sunitinib has also been associated with electrophysiological disturbances and an increased 503 
pro-arrhythmic relative risk of developing QTc interval prolongation (Ghatalia et al. 2015; 504 
Schmidinger et al. 2008).  Several studies show that Sunitinib could potentially block human 505 
ether-a-go-go-related gene (hERG) potassium channels and cause irregular contractions 506 
(Doherty et al. 2013; Guo et al. 2013). The in vitro study by Thijs et al. 2015 investigated the 507 
effect of Sunitinib on the contractile force measured during normal pacing or after simulated 508 
ischemia on isolated human atrial trabeculae from patients awaiting coronary artery bypass 509 
graft and/or aorta valve replacement. They showed that treatment with 81.3 nM Sunitinib did 510 
not attenuate the recovery in contractile force of atrial cardiomyocytes after simulated 511 
ischemia and reperfusion compared to vehicle treated atrial cardiomyocytes, and thus they 512 
concluded that the development of heart failure in patients treated with Sunitinib could not be 513 
explained by an acute cardiotoxic Sunitinib stimulation of cardiomyocytes. However, it 514 
should be noted that they used a 12-times lower Sunitinib dose compared to what we have 515 
used in this study, and thus they might have not used a dose of Sunitinib in the toxic range 516 
(Thijs et al. 2015). 517 
 518 
Modulation of ASK1 and its downstream targets MKK7 and JNK have been shown to play 519 
important roles in regulating cardiomyocyte survival, apoptosis, hypertrophic remodeling and 520 
intracellular signalling associated with heart failure (Mitchell et al. 2006). Therefore, we 521 
hypothesised that successful modulation of the ASK1/MKK7/JNK pathway would produce an 522 
effective cardioprotective treatment against Sunitinib induced cardiotoxicity. 523 
 524 
As we were interested in the ASK1/MKK7/JNK signalling pathway we targeted ASK1 with 525 
NQDI-1. Administration of the ASK1 specific inhibitor NQDI-1 resulted in abrogation of the 526 
some cardiotoxic effects of Sunitinib. This study therefore, demonstrates the potentially 527 
pivotal role that this kinase and the related pathway could play in protecting the heart from 528 
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Sunitinib induced cardiotoxicity. These observations are in accordance with other studies 529 
that have also implicated the involvement of ASK1 in cardioprotection in other mammalian 530 
models (Boehm 2015; Hao et al. 2016; He et al. 2003). Furthermore, inhibition of ASK1 with 531 
thioredoxin results in reduction of infarct size compared to ischemic/reperfusion control 532 
hearts (Gerczuk et al. 2012; Huang et al. 2015; Zhang et al. 2007).  533 
 534 
ASK1 signalling pathway is facilitated through two main routes: either (i) MKK4/7 and JNK, 535 
or (ii) MKK3/6 and p38 (Ichijo et al. 1997). As mentioned in the introduction the study by 536 
Izumiya et al. 2003 showed the importance of ASK1 during angiotensin II induced 537 
hypertension and cardiac hypertrophy in mice, as ASK1 knockout mice failed to develop 538 
cardiac hypertrophy and remodelling through both JNK and p38 (Izumiya et al. 2003). In 539 
another study by Yamaguchi et al. 2003 knockout of ASK1 in mice was also linked to 540 
cardioprotection through the JNK pathway, as coronary artery ligation or thoracic transverse 541 
aortic constriction in ASK1 deficient hearts showed no morphological or histological defects. 542 
Both left ventricular end-diastolic and end-systolic ventricular dimensions were increased 543 
less then wild-type mice, and the decreases in fractional shortening in both experimental 544 
models wereas less when compared with wild-type mice (Yamaguchi et al. 2003). However, 545 
in a study by Taniike et al. 2008 when ASK1 knockout mice were subjected to mechanical 546 
stress it resulted in exaggerated hearth growth and hypertrophy development through p38 547 
pathway (Taniike et al. 2008). It is worth noting that attenuation of ASK1 by NQDI-1 during 548 
normoxic conditions and Sunitinib treatment could have affected the MKK3/6 and p38 549 
signalling pathway, which would have led to the conflicting results that we observe during 550 
our study: tThere was a significant reduction in infarct size when Sunitinib was administered 551 
in the presence of the ASK-1 inhibitor NQDI-1, however administration of NQDI-1 alone also 552 
increased the infarct size. The increase in infarct size with NQDI-1 was not as profound as 553 
the increase observed with Sunitinib (Fig 1).  554 
 555 
NQDI-1 is a recently discovered highly specific ASK1 inhibitor. In the presence of 25 µM 556 
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NQDI-1 the residual activity of ASK1 is reduced to 12.5 % using the ɣ-32P-ATP in vitro 557 
kinase assay model. By using the same assay model Volynetys and colleagues determined 558 
the residual activity of the tyrosine protein kinase fibroblast growth factor receptor 1 (FGFR1) 559 
which was measured to be 44 % after 25 µM NQDI-1 exposure (Volynets et al. 2011). 560 
FGFR1 as a key component involved in in vivo cardiomyocyte proliferation during early 561 
stage heart development (Mima et al. 1995). Furthermore, FGFR1 is an essential regulator 562 
of coronary vascular development through Hedgehog signalling activation, which in the adult 563 
heart leads to increased coronary vessel density (Lavine et al. 2006). It is therefore possible 564 
that NQDI-1 is blocking FGFR1 directly in the treated hearts of our study and thereby 565 
exerting a slight increase in infarct size compared to the control.  566 
 567 
In addition, NQDI-1’s specificity towards other kinases has yet to be determined. In particular 568 
its homologue apoptosis signal-regulating kinase 2 (ASK2) may potentially be inhibited by 569 
NQDI-1 (Hattori et al. 2009). Both ASK1 and ASK2 is expressed in the heart (Iriyama et al. 570 
2009). ASK2 is only stable and active when it forms a heteromeric complex with ASK1. 571 
ASK2 mediate its stress response from the stable ASK1-ASK2 heteromeric complex 572 
platform through both JNK and p38 and induce apoptosis. Furthermore, ASK1 and AS2 are 573 
able to activate each other, and thus ASK1 assists ASK2 with ASK2 regulatory mechanisms 574 
in addition to stabilising and activating ASK2 (Takeda et al. 2007). It is therefore very likely 575 
that NQDI-1 will affect the ASK2 mediated signalling. Several studies by the team of Kataoka 576 
have revealed the involvement of ASK2 during hypertension, cardiac hypertrophy and 577 
remodelling development. They have shown that ASK2 deficient mice have a significantly 578 
higher blood pressure and increased left ventricular weight then wild type mice, with an 579 
underlying analysis revealing that perivascular and interstitial myocardial fibrosis was 580 
increased (Kataoka 2008, 2009, 2010, 2011). Therefore, the relatively small adverse effect 581 
of NQDI-1 administration on producing an increased infarct size could also be caused by the 582 
NQDI-1 effect through attenuated ASK2 signalling. Therefore, the cardiac adverse effect of 583 
NQDI-1 upon increased infarct size detected in this study could also be caused by the NQDI-584 
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1 effect through attenuated ASK2 signalling.    585 
 586 
Further studies are required to unravel the underlying mechanisms associated with the 587 
cardiac tissue injury and haemodynamic responses observed upon NQDI-1 stimuli to assess 588 
if p38, FGFR1, and/or ASK2 are involved. Also, other concentration of NQDI-1 treatment of 589 
hearts should be investigated, as lower concentrations of NQDI-1 most likely would cause 590 
less cardiac adverse effects. 591 
 592 
4.2. Profiling of cardiotoxicity linked microRNAs  593 
MicroRNAs have been shown to have important roles in tissue formation and function in 594 
response to injury and disease. The microRNAs miR-1, miR-27a, miR-133a and miR-133b 595 
have been shown to produce differential expression patterns during the progression of heart 596 
failure (Akat et al. 2014; Tijsen et al. 2012). Here we investigate the altered expression 597 
profiles of microRNAs miR-1, miR-27a, miR-133a and miR-133b after Sunitinib-induced 598 
cardiotoxicity with or without the ASK1 inhibitor NQDI-1 (Fig 2A-D). To the best of our 599 
knowledge there are no other studies showing a significant altered expression of miR-1, 600 
miR-27a, miR-133a and miR-133b after Sunitinib treatment. A reduction in hERG potassium 601 
channels expression causes the delayed myocyte repolarisation attributed to a long QT 602 
interval and interestingly the 3’ untranslated region of hERG potassium channel transcripts 603 
have a partial complimentary miR-133a target site (Xiao et al. 2007). The current study 604 
shows an increase in miR-133a expression following Sunitinib treatment, which was 605 
attenuated with NQDI-1 co-administration (Fig 2C). This could imply that miR-133a 606 
overexpression inhibits the hERG potassium channel, which would have a negative impact 607 
on the electrophysiological response (Xu et al. 2007). Over expression of miR-133a has also 608 
been shown to have negative effects on cardiomyocyte proliferation and survival (Liu et al. 609 
2008), which corroborates the results from the current study.  610 
 611 
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In the heart miR-1 and miR-133 maintain the heart beat rhythm by regulating the cardiac 612 
conduction system (Kim 2013). Furthermore, miR-1 and miR-133 are downregulated during 613 
cardiac hypertrophy in both mouse and human models. In vitro studies have shown that the 614 
overexpression of miR-133 inhibits cardiac hypertrophy, whereas inhibition of miR-133 615 
induces more pronounced hypertrophy (Care et al. 2007). In addition, a decreased in cardiac 616 
expression of miR-133b is sufficient to induce hypertrophic gene expression (Sucharov et al. 617 
2008). In support of these studies our analysis shows that the miR-133b expression is 618 
increased during NQDI-1 mono-therapy and co-administration of Sunitinib and NQDI-1 (Fig 619 
2C),In support of these studies our analysis shows that the miR-133b expression is 620 
increased during NQDI-1 mono-therapy and co-administration hearts (Fig 2C), thus 621 
protecting the heart against hypotrophy/cardiac damage development, which is the same 622 
pattern as we observe in the infarct to risk analysis. 623 
 624 
The miR-27a expression has been observed to downregulate FOXO-1 protein, a 625 
transcription factor which regulates genes involved in the apoptotic response, cell cycle, and 626 
cellular metabolism (Guttilla and White 2009). Moreover, miR-27a is downregulated in 627 
coronary sinus samples of heart failure patients (Marques et al. 2016). The increase in miR-628 
27a expression in our study during NQDI-1 mono-therapy and co-administration of Sunitinib 629 
and NQDI-1 The increase in miR-27a expression in our study during NQDI-1 mono-therapy 630 
and co-administration hearts (Fig 2B) support the findings from these studies as the link 631 
increased miR-27 expression to reduced apoptosis, which is what we observe in the infarct 632 
to risk analysis.  633 
 634 
4.3. Sunitinib treatment supresses the ASK1/MKK7/JNK pathway 635 
4.3.1. ASK1 636 
Western blot assessment of Sunitinib treated hearts showed a significant decrease in p-637 
ASK1 when compared to control perfused hearts, and this decrease in p-ASK1 levels was 638 
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abrogated with NQDI-1 co-administration. However, in p-ASK1 levels from hearts subjected 639 
to Sunitinib and NQDI-1 co-administration were compared to control hearts we did observe a 640 
significant increase in p-ASK1. . However, if p-ASK1 levels in Sunitinib and NQDI-1 co-641 
administration hearts were compared to control hearts we did observe a significant increase 642 
in p-ASK1. Furthermore, NQDI-1 treated hearts had significantly decreased p-ASK1 levels 643 
when compared to control hearts (Fig 4A).  644 
ASK1 has multiple phosphorylation sites. The Akt/protein kinas B complex binds to and 645 
phosphorylates Ser83 of ASK1, resulting in the inhibition of ASK1-mediated apoptosis (Kim et 646 
al. 2001), the 14-3-3 interacts with phosphorylated Ser967 of ASK1 to block the function of 647 
ASK1 (Zhang et al. 1999), protein phosphatase 5 dephosphorylates Thr845 within the 648 
activation loop of ASK1 and thereby inhibits ASK1-mediated apoptosis (Morita et al. 2001), 649 
while Ser1034 phosphorylation suppresses ASK1 proapoptotic function (Fujii et al. 2004). 650 
ASK1 undergoes auto-phosphorylation at the Thr845 (Tobiume et al. 2002). It is possible that 651 
auto-phosphorylation increased when Sunitinib was combined with NQDI-1, which led to the 652 
increased levels of p-ASK1 identified by western blot analysis. In its inactive form, ASK1 is 653 
complexed with thioredoxin (Saitoh et al. 1998). It has been proposed that auto-654 
phosphorylation at Thr845 is increased in response to H2O2 treatment, due to H2O2 preventing 655 
thioredoxin from complexing with ASK1. This suggests that ASK1 activation is due to 656 
oxidative stress (Tobiume et al. 2002).  An increase in p-ASK1 could indicate increased 657 
levels of oxidative stress, which potentially reduced cardiac function and generated a level of 658 
infarct when NQDI-1 was administered alone compared to control.  659 
 660 
 Attenuation of ASK1 by the specific inhibitor NQDI-1 produces a protective role in the heart 661 
compared to Sunitinib treatment alone. In this study we have focused on the ASK1 Thr845 662 
phosphorylation site, however, in future studies it would be interesting to investigate the 663 
ASK1 Ser967 phosphorylation, as phosphorylation at this site has been linked to 664 
cytoprotection (Kim et al. 2009). Another interesting aspect would be to identify if NQDI-1 is 665 
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able to inhibit the ASK1 homologue ASK2 as indicated by Nomura et al. 2013 (Nomura et al. 666 
2013) and establish the Ki and IC50 values are.  667 
 668 
ASK1 is also a key mediator of apoptotic signalling (Hattori et al. 2009; Ichijo et al. 1997) and 669 
the team of Huynh et al. 2011 investigated the expression of ASK1 in tumours lysates from 670 
mice bearing 06-0606 tumours treated with 40 mg/kg/day Sunitinib for 11 days (Huynh et al. 671 
2011). Their study showed a significant increase in total ASK1 levels after Sunitinib 672 
treatment compared to vehicle treated 06-0606 tumour expressing mice, however, in our 673 
study the expression of total ASK1 levels in left ventricular coronary tissue did not differ in 674 
hearts perfused with Sunitinib compared to vehicle treated hearts. 675 
 676 
4.3.2. MKK7 677 
We assessed MKK7 expression level at both transcriptional and post-translational levels in 678 
hearts treated with Sunitinib with and without the upstream ASK1 inhibitor NQDI-1. There 679 
was a strong tendency for MKK7 mRNA expression to be decreased in Sunitinib perfused 680 
hearts compared to control, but without significance. There was a strong tendency of 681 
decreased MKK7 mRNA expression in Sunitinib perfused hearts compared to control, but 682 
without significance. The expression of MKK7 mRNA was increased significantly in Sunitinib 683 
and NQDI-1 co-treated hearts compared to Sunitinib perfused hearts, and NQDI-1 solo 684 
treatment did not alter the MKK7 mRNA expression compared to control hearts (Fig 3). The 685 
p-MKK7 level was significantly decreased in Sunitinib treated hearts when compared to 686 
control, and the p-MKK7 decrease is attenuated by NQDI-1 co-administration. The p-MKK7 687 
levels are significantly decreased in Sunitinib and NQDI-1 co-treatment and NQDI-1 solo-688 
treatment hearts compared to control hearts (Fig 4B). We believe that this is the first study to 689 
investigate the expression of MKK7 after Sunitinib therapy. 690 
 691 
MKK7 has a vital role in protecting the heart from hypertrophic remodelling and 692 
cardiomyocytes apoptosis during stress and therefore the transition into heart failure 693 
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(Mitchell et al. 2006). Studies by Liu et al. 2011 revealed the importance of MKK7 by 694 
demonstrating that deprivation of MKK7 in cardiomyocytes provokes heart failure in mice 695 
when exposed to pressure overload (Liu et al. 2011). In addition to this, it has been shown 696 
that inhibition and specific knockout of MKK7 increases the sensitivity of hepatocytes to 697 
tumour necrosis factor alpha-induced apoptosis (Jia et al. 2015). Treatment with Sunitinib in 698 
rat hearts in the current study down regulates both mRNA and phosphorylated protein levels 699 
of MKK7. These studies suggest an important role of MKK7 in the maintenance of heart 700 
homeostasis and expression of associated genes are important during cardiac hypertrophy 701 
and heart failure.  702 
 703 
MKK7 contains an ATP binding domain which could be inhibited by the ATP analogue, 704 
Sunitinib (Roskoski 2007; Shukla et al. 2009; Song et al. 2013). It is therefore possible that 705 
Sunitinib has an inhibitory effect on the MKK7/JNK signal transduction pathway. With 706 
reduced MKK7 activity demonstrating both an incline towards cardiomyocyte damage and a 707 
reversal of anti-tumour effects of chemotherapy, it would be interesting to assess both the 708 
changes in expression levels and levels of phosphorylated MKK7 during Sunitinib treatment 709 
affecting the heart in future studies. It may therefore be possible to identify a link between 710 
MKK7 expression and tyrosine kinase inhibitor-induced cardiotoxicity.  711 
 712 
Co-treatment of Sunitinib and NQDI-1 increases the level of p-MKK7 to levels compared to 713 
Sunitinib treated hearts, restoring them almost back to the p-MKK7 levels observed in 714 
control hearts. This could suggest that phosphorylated MKK7 is required to maintain at a 715 
stable level to prevent damage to the heart. To illustrate this upregulation of transforming 716 
growth factor beta has been found in compensatory hypertrophy, myocardial remodelling 717 
and heart failure (Rosenkranz 2004). However, if MKK7 is removed entirely from the JNK 718 
pathway cardiomyocyte damage ensues (Liu et al. 2011). Tang et al. 2012 demonstrated 719 
that by causing an upregulation of MKK7 in hepatoma cells with the treatment with Alpinetin 720 
it was possible to arrest cells in the G0/G1 phase of the cell cycle. However, by inhibiting 721 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 
 
27 
 
MKK7 the anti-tumour effect of the delta-opioid receptor agonist cis-diammined 722 
dichloridoplatinum was reversed (Tang et al. 2012). This suggests that by agonising MKK7 it 723 
may be possible to both enhance anti-cancer properties of chemotherapy agents, as well as 724 
limiting apoptosis as the cell cycle is arrested. 725 
 726 
4.3.3. JNK 727 
Administration of Sunitinib decreased the p-JNK levels significantly when compared to 728 
control hearts, and this decrease was abrogated with NQDI-1 co-treatment. Treatment with 729 
NQDI-1 however also decreased the p-MKK7 levels when compared to control perfused 730 
hearts (Fig 4C).  731 
 732 
Many JNK knock out models have been used to determine the role of JNK in the 733 
development of cardiac dysfunction. Kaiser et al. 2005 demonstrated the importance of JNK 734 
in ischemia-reperfusion injury. They showed that a reduction in JNK activity in the heart 735 
resulted in a reduced level of cardiac injury and cellular apoptosis. The same study 736 
demonstrated an increase in JNK activity by using mouse models overexpressing MKK7 in 737 
the heart, and this caused a significant protection against ischemia-reperfusion injury (Kaiser 738 
et al. 2005). This highlights the complexity of JNK signalling. In this study, a significant 739 
decrease in JNK phosphorylation was identified when hearts were treated with Sunitinib. In 740 
addition, NQDI-1 treatment had a tendency to increase in JNK phosphorylation. It has been 741 
established that a reduction in JNK activation is associated with cardiac hypertrophy and 742 
cardiovascular dysfunction (Pan et al. 2014). The reduction in JNK activation caused by the 743 
treatment of Sunitinib could also explain the increased infarct size and irregularities found in 744 
the haemodynamic data.  745 
 746 
Our study contradicts some previous studies, for example Wang et al. 1998 investigated the 747 
role of MKK7 in cardiac hypertrophy in neonatal myocytes (Wang et al. 1998). Transgenic 748 
neonatal rat cardiomyocytes expressing wild type MKK7 and a constitutively active mutant of 749 
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MKK7 were created. This study demonstrated JNK specific activation by MKK7 and showed 750 
the key role of the JNK pathway in cardiac hypertrophy as cells infected with the 751 
constitutively active form of MKK7 adopted characteristic features of myocardial stress 752 
(Wang et al. 1998).  753 
 754 
The study by Fenton et al 2010 looked at the expression of JNK in papillary cancer cells with 755 
RET/PTC1 rearrangement treated with Sunitinib (Fenton et al. 2010). Sunitinib inhibited 756 
proliferation of these RET/PTC1 subcloned papillary cancer cells, and furthermore inhibited 757 
the JNK phosphorylation in the cytoplasm of the papillary cancer cells. In our study the 758 
expression of p-JNK levels in left ventricular coronary tissue was also reduced in hearts 759 
perfused with Sunitinib compared to vehicle treated hearts. 760 
 761 
In summary, Sunitinib administration resulted in significant reduction in p-ASK1, p-MKK7 and 762 
p-JNK levels, whilst NQDI-1 co-administration counteracted this increase. It is worth noting 763 
that MKK7 is activated through phosphorylation at a special site at the C-terminal kinase 764 
domain core called the "Domain for Versatile Docking" (DVD), which includes serine-765 
threonine sites (Wang et al. 2007). Sunitinib does not not discriminate between inhibition of 766 
tyrosine kinases or serine-threonine kinases (Karaman et al. 2008). Therefore, Sunitinib 767 
might potentially inhibiting serine-threonine kinases, however, it is much more likely that 768 
Sunitinib inhibits tyrosine kinases as expected, resulting in the downstream inhibition of 769 
ASK1, which then results in a downstream inhibition of MKK7 and JNK. However, more 770 
detailed investigations into the pathway involvement are required to fully elucidate the 771 
intracellular signalling pathways. In addition, the increase in p-ASK1, p-MKK7 and p-JNK 772 
levels that we observe in the presence of both Sunitinib and NQDI-1, when compared to 773 
Sunitinib perfused hearts, could be due to the fact that we only assessed the 774 
phosphorylation of ASK1 at Thr845, however, it is possible that NQDI-1 blocks both Ser83 and 775 
Thr845 of ASK1, and further investigations of phosphorylation activity at both sides could 776 
clarify this issue. This altered pattern in ASK1/MKK7/JNK pathway phosphorylation suggests 777 
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that Sunitinib has a direct effect on part of the ASK1/MKK7/JNK pathway. In summary, 778 
Sunitinib administration resulted in significant reduction in p-ASK1, p-MKK7 and p-JNK 779 
levels, whilst NQDI-1 co-administration counteracted this increase. It is possible that NQDI-1 780 
blocks both Ser83 and Thr845, and that the increase in p-ASK1, p-MKK7 and p-JNK levels that 781 
we observe in the presence of both Sunitinib and NQDI-1 when compared to Sunitinib 782 
perfused hearts is due to fact only phosphorylation of ASK1 at Thr845 was assessed. This 783 
altered pattern in ASK1/MKK7/JNK pathway phosphorylation suggests that Sunitinib has a 784 
direct effect on part of the ASK1/MKK7/JNK pathway.  785 
 786 
4.4. The anti-cancer properties of Sunitinib were enhanced by NQDI-1 treatment 787 
It is well established that Sunitinib achieves anti-tumour effects by inhibiting tyrosine kinases, 788 
which have been over-expressed in cancer cells (Krause and Van Etten 2005). Sunitinib has 789 
previously been shown to directly inhibit the survival and proliferation of a variety of cancer 790 
cells, including leukaemia cells (Ilyas 2016).  791 
 792 
We demonstrated a dose dependant decline in the cell viability of HL60 cells when treated 793 
with Sunitinib (Fig 5A). This produced an IC50 value of 6.16 µM. Our results are in line with 794 
existing data on the anti-proliferative effect of Sunitinib on HL60 cells. Sunitinib has 795 
previously been shown to reduce the level of HL60 cell survival in a dose dependant manor 796 
using a cell-titre blue reagent proliferation assay. This produced an IC50 value of 5.7 µM after 797 
48 hrs of Sunitinib treatment (Ilyas 2016).  Another group performed an MTT assay on a 798 
variety of acute myelogenous leukaemia cell lines and found Sunitinib to have an IC50 values 799 
between 0.007-13 µM (Hu et al. 2008). 800 
 801 
To investigate the anti-proliferative effect of inhibition of the MKK7 pathway, HL60 cells were 802 
treated with Sunitinib in co-treatment with NQDI-1 and NQDI-1 alone (Fig 5A-B). NQDI-1 is a 803 
selective inhibitor for ASK1, the upstream regulator of MKK7. Previous studies have shown 804 
ASK1 to have a crucial role in a variety of organ systems. However, ASK1 has also been 805 
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shown to promote tumorigenesis in gastric cancer and promote the proliferation of cancer 806 
cells in skin cancer (Hayakawa et al. 2012; Iriyama et al. 2009).  807 
 808 
Inhibition of ASK1 with compound K811 has been shown to prevent cell proliferation in 809 
gastric cancer cell lines and reduce the size of xenograft tumours (Hayakawa et al. 2012). 810 
Recently, Luo et al. 2016, investigated the involvement of ASK1 during proliferation in 811 
pancreatic tumour cell line PANC-1 (Luo et al. 2016).  The knock-down of ASK1 in mice with 812 
pancreatic tumours reduced tumour growth, suggesting that ASK1 has an important role in 813 
pancreatic tumorigenesis. The same group also demonstrated a dose-dependent inhibition 814 
of the PANC-1 cell line when cells were treated with NQDI-1 at concentrations of 10 and 30 815 
µM. However, the inhibition of ASK1 did not increase levels of apoptosis.  816 
 817 
We have shown that increasing concentrations of NQDI-1 (0.2-200 µM) significantly reduce 818 
the level of viable HL60 cells at 100 and 200 µM. This could suggest that ASK1 is expressed 819 
at different levels in different cell types as a higher concentration was required in HL60 cells 820 
compared to PANC-1 cells. Interestingly, the increasing concentrations of Sunitinib with 2.5 821 
µM NQDI-1 enhanced the level of Sunitinib induced a reduction in HL60 cell proliferation. 822 
The reason for this is not yet clear and further investigation into this is required.  823 
 824 
As mentioned before NQDI-1 blocks FGFR-1 (Volynets et al. 2011). In cancer cells FGFR1 825 
inhibitors have shown to elicit direct anti-tumour effects. The FGFR-1 inhibitors being 826 
investigated in clinical trials for their anti-tumour qualities effecting various cancer types 827 
include AZD4547, BGJ398, Debio-1347 and dovitinib (Katoh 2016). The apoptotic effect of 828 
NQDI-1 we are observing in HL60 cells can therefore be a direct consequence of FGFR-1 829 
inhibition.  830 
 831 
In conclusion, our study demonstrates the potential of NQDI-1 as a valuable asset to cardiac 832 
injury through the ASK1/MKK7/JNK transduction pathway, which could potentially lead to 833 
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development of cardioprotective adjunct therapy during drug-induced cardiac injury. NQDI-1 834 
was observed to be cardioprotective as it reduced the Sunitinib-induced infarct size, and 835 
addition it increased the apoptotic effect of Sunitinib in HL60 cells. This could indicate that 836 
NQDI-1 - or an optimised derivative - could potentially be used as cardioprotective adjunct 837 
therapy in e.g. Sunitinib treated leukaemia patients, which would not only protect the 838 
patients’ hearts but also boost the anti-cancer abilities of Sunitinib.  839 
 840 
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Figure legends 853 
Figure 1: Infarct to whole heart ratio assessment. The hearts were drug perfused with 854 
Sunitinib and/or NQDI-1 for 125 min in an isolated Langendorff heart model. This establishes 855 
that Sunitinib-induced cardiotoxicity is reduced by ASK1 inhibitor NQDI-1. Groups: Control, 856 
Sunitinib (1 µM), Sunitinib (1 µM) and NQDI-1 (2.5 µM), and NQDI-1 (2.5 µM) (n=6 per 857 
group). Groups were assessed for statistical significance at each time point using one-way 858 
ANOVA. Control versus Sunitinib (***=P<0.001), Control versus Sunitinib+NQDI-1 859 
(**=P<0.01), Control versus NQDI-1 (*=P<0.05), or Sunitinib vs Sunitinib+NQDI-1 860 
(###=P<0.001). 861 
 862 
Figure 2: Cardiotoxicity linked microRNAs expression. The effect of Sunitinib (1 µM) and the 863 
co-administration of ASK1 inhibitor, NQDI-1 (2.5 µM), on the expression of cardiotoxicity 864 
linked microRNAs following 125 minute drug perfusion in an isolated heart Langendorff 865 
model. The qRT-PCR results are shown as the ratio of target microRNA normalised to U6 866 
with control group microRNA ratio set as 1 of microRNAs A) miR-1, B) miR-27a, C) miR-867 
133a and D) miR-133b. The ratio of target microRNA normalised to U6 is presented on a log 868 
scale. Groups: Control (n=6 for miR-1, miR-27a and miR-133a; n=5 for miR-133b), Sunitinib 869 
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(1 µM) (n=6 for miR-1 and miR-27a; n=5 for miR-133a and miR-133b), Sunitinib (1 µM) and 870 
NQDI-1 (2.5 µM) (n=6 for miR-1, miR-27a, miR-133a and miR-133b), and NQDI-1 (2.5 µM) 871 
(n=4 for miR-1, miR-27a, miR-133a and miR-133b). Groups were assessed for statistical 872 
significance at each time point using one-way ANOVA. Control versus Sunitinib 873 
(***=P<0.001), Control versus Sunitinib+NQDI-1 (*=P<0.05, **=P<0.01), Control versus 874 
NQDI-1 (**=P<0.01, ***=P<0.001), or Sunitinib vs Sunitinib+NQDI-1 (#=p<0.05, 875 
###=P<0.001). 876 
 877 
Figure 3: MKK7 mRNA expression levels. The qRT-PCR assessment of MKK7 mRNA 878 
expression levels in an isolated heart Langendorff model. The qRT-PCR results are shown 879 
as the ratio of MKK7 mRNA normalised to GAPDH with control group ratio set as 1. Groups: 880 
Control (n=5), Sunitinib (1 µM) (n=6), Sunitinib (1 µM) and NQDI-1 (2.5 µM) (n=3), and 881 
NQDI-1 (2.5 µM) (n=3). Groups were assessed for statistical significance at each time point 882 
using one-way ANOVA. Control versus Sunitinib, Control versus Sunitinib+NQDI-1, Control 883 
versus NQDI-1, or Sunitinib vs Sunitinib+NQDI-1 (#=p<0.05). 884 
 885 
Figure 4: ASK1/MKK7/JNK pathway western blot assessment. A) p-ASK1, B) p-MKK7, and 886 
C) p-JNK phosphorylation levels in an isolated heart Langendorff model. Sorbitol was 887 
included as a positive control in p-MKK7 Western blot analysis (n=4). Groups: Control (n=6 888 
for p-ASK1; n=4 for p-MKK7 and p-JNK), Sunitinib (1 µM) (n=5 for p-ASK1; n=4 for p-MKK7 889 
and p-JNK), Sunitinib (1 µM) and NQDI-1 (2.5 µM) (n=6 for p-ASK1; n=4 for p-MKK7 and p-890 
JNK) and NQDI-1 (2.5 µM) (n=5 for p-ASK1; n=4 for p-MKK7 and p-JNK). Groups were 891 
assessed for statistical significance at each time point using one-way ANOVA. Control 892 
versus Sunitinib (***=P<0.001), Control versus Sunitinib+NQDI-1 (*=p<0.05), Control versus 893 
NQDI-1 (**=P<0.01; ***=P<0.001), or Sunitinib vs Sunitinib+NQDI-1 (#=p<0.05; 894 
###=P<0.001). 895 
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Figure 5: HL60 cell viability. HL60 cells (105 cells/ml) were incubated for 24 hours with 897 
control or with increasing concentrations of A) Sunitinib (0.1 – 10 μM) or Sunitinib (0.1 – 10 898 
μM) + NQDI-1 (2.5 µM) or B) NQDI-1 (0.2 µM – 200 μM). Groups were assessed for 899 
statistical significance at each time point using one-way ANOVA. Control versus Sunitinib 900 
(*=P<0.05 and ***=P<0.001), Control versus NQDI-1 (*=P<0.05 and ***=P<0.001), or 901 
Sunitinib vs Sunitinib+NQDI-1 (###=p<0.001). Figure 1: Infarct to whole heart ratio 902 
assessment. The hearts were drug perfused with Sunitinib and/or NQDI-1 for 125 min in an 903 
isolated Langendorff heart model. This establishes that Sunitinib-induced cardiotoxicity is 904 
reduced by ASK1 inhibitor NQDI-1. Groups: Control, Sunitinib (1 µM), Sunitinib (1 µM) and 905 
NQDI-1 (2.5 µM), and NQDI-1 (2.5 µM) (n=6 per group). Groups were assessed for 906 
statistical significance at each time point using one-way ANOVA. Control versus Sunitinib 907 
(red ***=P<0.001), Control versus Sunitinib+NQDI-1 (green **=P<0.01), Control versus 908 
NQDI-1 (blue *=P<0.05), or Sunitinib vs Sunitinib+NQDI-1 (purple $$$=P<0.001). 909 
 910 
Figure 2: Cardiotoxicity linked microRNAs expression. The effect of Sunitinib (1 µM) and the 911 
co-administration of ASK1 inhibitor, NQDI-1 (2.5 µM), on the expression of cardiotoxicity 912 
linked microRNAs following 125 minute drug perfusion in an isolated heart Langendorff 913 
model. The qRT-PCR results are shown as the ratio of target microRNA normalised to U6 914 
with control group microRNA ratio set as 1 of microRNAs A) miR-1, B) miR-27a, C) miR-915 
133a and D) miR-133b. The ratio of target microRNA normalised to U6 is presented on a log 916 
scale. Groups: Control (n=6 for miR-1, miR-27a and miR-133a; n=5 for miR-133b), Sunitinib 917 
(1 µM) (n=6 for miR-1 and miR-27a; n=5 for miR-133a and miR-133b), Sunitinib (1 µM) and 918 
NQDI-1 (2.5 µM) (n=6 for miR-1, miR-27a, miR-133a and miR-133b), and NQDI-1 (2.5 µM) 919 
(n=4 for miR-1, miR-27a, miR-133a and miR-133b). Groups were assessed for statistical 920 
significance at each time point using one-way ANOVA. Control versus Sunitinib (red 921 
***=P<0.001), Control versus Sunitinib+NQDI-1 (green *=P<0.05, **=P<0.01), Control versus 922 
NQDI-1 (blue **=P<0.01, ***=P<0.001), or Sunitinib vs Sunitinib+NQDI-1 (purple $=p<0.05, 923 
$$$=P<0.001). 924 
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 925 
 926 
Figure 3: MKK7 mRNA expression levels. The qRT-PCR assessment of MKK7 mRNA 927 
expression levels in an isolated heart Langendorff model. The qRT-PCR results are shown 928 
as the ratio of MKK7 mRNA normalised to GAPDH with control group ratio set as 1. Groups: 929 
Control (n=5), Sunitinib (1 µM) (n=6), Sunitinib (1 µM) and NQDI-1 (2.5 µM) (n=3), and 930 
NQDI-1 (2.5 µM) (n=3). Groups were assessed for statistical significance at each time point 931 
using one-way ANOVA. Control versus Sunitinib, Control versus Sunitinib+NQDI-1, Control 932 
versus NQDI-1, or Sunitinib vs Sunitinib+NQDI-1 (purple $=p<0.05). 933 
 934 
Figure 4: ASK1/MKK7/JNK pathway western blot assessment. A) p-ASK1, B) p-MKK7, and 935 
C) p-JNK phosphorylation levels in an isolated heart Langendorff model. Sorbitol was 936 
included as a positive control in p-MKK7 Western blot analysis (n=4). Groups: Control (n=6 937 
for p-ASK1; n=4 for p-MKK7 and p-JNK), Sunitinib (1 µM) (n=5 for p-ASK1; n=4 for p-MKK7 938 
and p-JNK), Sunitinib (1 µM) and NQDI-1 (2.5 µM) (n=6 for p-ASK1; n=4 for p-MKK7 and p-939 
JNK) and NQDI-1 (2.5 µM) (n=5 for p-ASK1; n=4 for p-MKK7 and p-JNK). Groups were 940 
assessed for statistical significance at each time point using one-way ANOVA. Control 941 
versus Sunitinib (red ***=P<0.001), Control versus Sunitinib+NQDI-1 (green *=p<0.05), 942 
Control versus NQDI-1 (blue **=P<0.01; ***=P<0.001), or Sunitinib vs Sunitinib+NQDI-1 943 
(purple $=p<0.05; $$$=P<0.001). 944 
 945 
Figure 5: HL60 cell viability. HL60 cells (105 cells/ml) were incubated for 24 hours with 946 
control or with increasing concentrations of A) Sunitinib (0.1 – 10 μM) or Sunitinib (0.1 – 10 947 
μM) + NQDI-1 (2.5 µM) or B) NQDI-1 (0.2 µM – 200 μM). Groups were assessed for 948 
statistical significance at each time point using one-way ANOVA. Control versus Sunitinib 949 
(red *=P<0.05 and ***=P<0.001), Control versus NQDI-1 (blue *=P<0.05 and ***=P<0.001), 950 
or Sunitinib vs Sunitinib+NQDI-1 (purple $$$=p<0.001). 951 
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